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Health policy makers are struggling to manage health care and spending. To identify 
strategies for improving health quality and reducing health spending, policy makers need to first 
understand health risks and outcomes. Despite lacking some desirable clinical detail, existing health 
care databases, such as national health surveys and claims and enrollment data for insured 
populations, are often rich in information relating patient characteristics to heath risks and 
outcomes. They typically encompass more inclusive populations than can feasibly be achieved 
with new data collection and are valuable resources for informing health policy. This dissertation 
illustrates how the Medicare Current Beneficiary Survey (MCBS) and MassHealth data can be 
used to develop models that provide useful estimates of risks and health quality measures. It 
provides insights into: 1) the benefits of a proxy for the Framingham cardiovascular disease (CVD) 
risk score, that relies only on variables available in the MCBS, to target health interventions to 
policy-relevant subgroups, such as elderly Medicare beneficiaries, based on their risk of developing 
CVD, 2) the importance of setting appropriate risk-adjusted quality of care standards for 
accountable care organizations (ACOs) based on the characteristics of their enrolled members, and 
3) the outsized effect of high- frequency hospital users on re-admission measures and possibly 
other quality measures. This work develops tools that can be used to identify and support care of 
vulnerable patients to both improve their health outcomes and reduce spending – an important step 
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1.1 Specific Aims 
The United States spends more per capita on health care than any other nation, 
while having the lowest life expectancy and some of the worst health outcomes among 
high-income nations. 1,2 It is critical to consider optimal allocation of the limited 
resources and set up priorities for health quality improvement. One strategy to curb health 
care spending while improving health quality is to identify the relatively small portion of 
patients with costly chronic conditions, such as cardiovascular disease (CVD), that 
account for a large share of spending. It is estimated that only about 5% percent of the 
U.S. population is responsible for almost 50% percent of all spending. 3 Hence, efficient 
population-based health interventions targeted at high-risk patients to prevent, manage, 
and reduce the burden of morbidity and mortality associated with expensive diseases 
could lead to both savings and better health.    
Another strategy to reduce health spending and improve health quality is to shift 
from volume-based payment models, such as fee-for-service (FFS) to value-based 
models, such as patient-centered medical homes, value-based purchasing programs, and 
accountable care organizations (ACOs). Traditional FFS payment, where healthcare 
providers are reimbursed by payers (e.g.; Medicare, MassHealth, private insurance 
companies) based on the number and nature of services provided, has led to ever-
increasing costs for an aging population with a substantial burden of debilitating illnesses 
and disabilities. Moreover, the FFS structure encourages overutilization of medical 
services by physicians and patients, which drives up healthcare spending. A key goal of 







hospitals, and other health care providers to contract together in networks, such as ACOs, 
to provide comprehensive, effective, efficient, safe and timely care to their enrolled 
populations. It is hoped that ACOs, by coordinating care for their members, can improve 
quality while reducing spending. 4,5 Payers pay ACOs to cover a defined set of services 
for the members they enroll. ACOs are then held responsible for providing those services, 
and for the overall health of their members. To judge the care provided by ACOs, payers 
develop quality measures and reward ACOs for delivering high quality and efficient 
health care, often  giving them an opportunity to share in any resulting savings. 6 ACOs 
may also be ineligible for shared savings or even responsible to pay penalties when they 
do not meet quality benchmarks. 7–9 Hence, ACOs’ profits are linked to the quality of 
health outcomes and efficiency rather than the volume of services delivered to their 
members. 
Whether health policy makers or payers seek to identify subgroups at high risk for 
an expensive disease or judge the quality of care offered by an ACO to their enrollees, 
they need to capture health risks and outcomes accurately. Even though the use of 
electronic health records, which contain massive amounts of these data collected from 
patients, health providers, and insurance companies, has increased over time; some direct 
measures may still be hard and expensive to abstract, such as those entered in free-text 
format. Moreover, acquiring specific risk and outcome information through 
questionnaires may limit the number and kinds of individuals that are included in a study, 
which could threaten the validity and reliability of findings. Existing health care 







relatively less expensive, more readily available, include larger and more diverse 
populations, and allow for a broader range of analyses for addressing health policy 
questions than would typically be obtainable with data newly gathered for a specific 
study. Despite lacking some desirable clinical detail, existing health care databases are 
often rich in information relating patient characteristics to heath risks and outcomes. 
Two important types of existing databases are claims data for insured populations 
and national health surveys. Claims are transactions between patients and healthcare 
providers (e.g. hospitals, pharmacies, other medical professionals) that are submitted for 
payment to public and private payers. National surveys, on the other hand, are 
representative samples of the U.S. population or specific subgroups and may sometimes 
be designed for specific research areas. For instance, the Medicare Current Beneficiary 
Survey (MCBS) is a nationally representative probability sample of Medicare 
beneficiaries sponsored by the Centers for Medicare and Medicaid Services (CMS). 10 
Another national database is the American Community Survey (ACS), an ongoing survey 
conducted by the U.S. Census Bureau. 11 It is a premier source for detailed information 
such as education, income, language proficiency, disability, employment, and housing 
characteristics (measured for groups of people who live close to each other). 
In this dissertation, we build models on existing databases that can help health 








1) To develop and validate a CVD risk prediction tool to better identify at-risk 
elderly Medicare subpopulations who are most likely to benefit from cost-effective 
interventions for prevention and /or management of CVD.  
2) To illustrate the value of risk adjusting quality measures using morbidity and 
social determinants of health (SDH) factors, using the example of 30-day hospital 
readmission rates. 
3) To describe the characteristics of high-frequency hospital users (4 or more 
hospital visits per year) and to assess the impact of their inclusion or exclusion on a 30-
day readmission quality measure. 
The purpose of the first aim was to develop a 3-year CVD risk score to use with 
the MCBS to identify at-risk Medicare beneficiaries aged 65 years and older to 
understand the extent to which effective targeting of interventions to high-risk people 
could improve outcomes or reduce costs. Our risk score uses variables readily available 
in MCBS, thereby providing an easy-to-implement enhancement to this important 
national data resource. This score may offer new opportunities for quantifying and 
monitoring CVD and its substantial effect on mortality, disability, and spending in 
Medicare beneficiaries. We hypothesized that our CVD risk score could improve CVD 
event prediction in the MCBS and provide insights for researchers and policy makers into 
how to target effective health interventions to Medicare subgroups, depending upon their 
CVD risk.  
The purpose of the second aim was to show how assessing health quality without 







harm ACOs that disproportionally serve vulnerable populations. 7–9 We used 30-day 
hospital readmission rate as an example, as high rates of readmission are often taken as a 
measure of poor quality of care and lowering these rates is thus seen as a good way to 
reduce health spending without harming health. 12 We estimated regression models 
predicting 30-day readmission rates from diagnoses and SDH factors using data from 
MassHealth, the Massachusetts Medicaid and Children's Health Insurance Program. We 
compared these models’ predicted rates with actual readmission rates for MassHealth 
managed care eligible population ages 18-64 and for subgroups of interest. We 
hypothesized that risk adjusting 30-day readmission rates for medical morbidity and SDH 
risk factors could allow for fairer comparisons across ACOs that appropriately account 
for the challenges and complexities inherent in caring for vulnerable patients. 
The goals of the third aim were to 1) better understand which MassHealth patients 
may be at risk for frequent hospital use and highest likelihood of readmission after 
hospitalization and 2) evaluate the extent to which including or excluding high-frequency 
users from the 30-day readmission measure changes its rate and variance. A better 
understanding of which patients may be at risk for frequent hospital use is important 
because many of their initial hospitalizations could perhaps be prevented through more 
effective and targeted interventions. Moreover, a better understanding of which patients 
are most likely to be readmitted after hospitalization may enable clinicians, ACOs, 
payers, and policy makers to focus efforts on patients who will benefit most from heath 







group of MassHealth beneficiaries are responsible for disproportionate hospitalization 
use and have an outsized effect on 30-day readmission and its variability. 
1.2 Background and Significance 
1.2.1 A CVD risk score that uses MCBS allows for a broader range of analyses for 
addressing health policy questions 
Policy makers increasingly rely on nationally representative datasets, such as 
MCBS, to assess the impact of alternate health interventions. MCBS contains a wealth of 
information for health policy research related to expensive chronic diseases and 
conditions such as CVD. More than one in three adults currently has CVD in the United 
States; 13 this number will likely increase as the U.S. population ages.  CVD is the 
leading cause of death and a major cause of disability. 14 Identifying individuals at high 
risk for CVD-related events, and their substantial effect on mortality and disability, is a 
priority. Older Americans at the highest risk of a CVD event – most of whom are 
Medicare beneficiaries will benefit most from targeted health interventions.  
The Framingham Risk Score (FRS), the most widely used tool for estimating 10-
year CVD risk, is powerful for classifying people according to their risk of a major CVD 
event. The traditional risk factors in the sex-specific FRS models for predicting CVD 
events are age, total cholesterol, high-density lipoprotein (HDL) cholesterol, systolic 
blood pressure (SBP), antihypertensive medication use, current smoking, and diabetes 
status. 15 Unfortunately, MCBS does not record either cholesterol or SBP measures. This 
makes MCBS less useful for studying distinct CVD risk subgroups – what treatments 







analyses for addressing public health and policy questions than would be possible using 
either survey or Medicare data alone. 10,16 Not only does the MCBS include a nationally 
representative sample of the US elderly, a high proportion of whom live with chronic 
conditions, it also contains information on health outcomes, use of health services, 
expenditures, and sources of payment. 10 The ability to predict CVD risk for MCBS 
respondents would make MCBS even more valuable for research and policy forecasting. 
To demonstrate the value of being able to calculate CVD risk within MCBS, we give an 
example of an important study where the authors used information on beneficiaries with 
CVD risk to examine the feasibility of a value-based insurance design intervention. 17 
Value-based insurance design provides financial incentives to increase medication 
adherence in subpopulations where adherence is expected to yield particularly high health 
benefits and long-term cost savings. Findings from this study suggest that  those at higher 
risk of CVD benefited more from reducing statin co-payments. 17 Our goal was to 
develop a proxy for the FRS that relies only on variables available in the MCBS, to 
improve the ability to measure CVD risk in this national survey dataset. This tool is 
intended for health policy development not for helping individual patients and clinicians 
decide on lifestyle modifications and/or CVD therapies. 
1.2.2 Risk adjustment of 30-day readmission may be beneficial for vulnerable 
populations and the ACOs that serve them 
Risk adjustment of quality measures is an approach intended to “level the playing 
field” by accounting for patient-mix differences among hospitals and health plans, so that 







re-hospitalization rate for hospital A is 15% and that for hospital B is 20%, it is tempting 
to conclude that hospital B provides poorer quality care. However, if hospital B attracts 
patients at substantially higher risk for re-hospitalization, a 20% readmission rate could 
reflect the effect of delivering excellent care to a population for whom an even higher 
readmission rate was expected. Risk adjustment is important for health quality measures, 
because patients’ health outcomes are usually driven not by quality of care alone, but also 
by patient characteristics, such as age, gender, chronic conditions, and SDH problems. 
ACOs that disproportionally serve and care for beneficiaries with high levels of 
morbidity burden and social risk factors are likely to perform poorly on ACO quality 
measures that are not risk adjusted, and may face unfair financial penalties. 18–20 This may 
translate into reluctance of ACOs to care for these beneficiaries, possibly increasing 
health disparities. In contrast, risk adjusted quality measures help protect ACOs that 
disproportionally serve medically and socially complex patients from unfair quality 
penalties. Plans with exceptionally vulnerable patients can use the extra dollars that risk 
adjustment may provide, for example, to design and implement interventions to deliver 
better care for their members, which could lead to better health for their high-risk 
members. 
In this dissertation, we illustrate the value of risk adjustment in the example of a 
30-day readmission measure for a health plan, since this outcome has been frequently 
used to measure and compare the performance of hospitals and is now coming into use 
for plans. 21 The goal is to encourage more attentive post-acute care and to reduce overall 







Medicaid  Services (CMS) penalizes hospitals for excessive unplanned readmissions9.  
The CMS has been publicly reporting risk-adjusted readmission rates for acute heart 
failure, pneumonia, and myocardial infarction for several years. 23 However, its risk-
adjustment models rely primarily on morbidity burden and do not account for other risk 
factors such as SDH variables. 24–26  We are aware of two studies that examined the 
impact of adjustment for social risk factors on readmission measure when comparing 
hospitals.27,28 However, these studies found inconsistent results, used limited SDH 
factors, and focused on Medicare elderly population with acute myocardial infarction, 
heart failure, or pneumonia only. Here, we examined all cause adult 30-day readmission 
rate as a measure of health plan quality in an entire Medicaid population, and using both 
medical and SDH factors, most notably serious mental illness and substance use disorder 
variables. 
1.2.3 High frequency hospital users may have an outsized effect on 30-day 
readmission and its variability 
Like other quality measures, 30-day readmission is based on clinical guidelines 
that apply to the general population or specified subgroups. However, even among 
targeted subpopulations, such as patients hospitalized for specific conditions, a small 
subgroup of individuals who frequently use hospitals may add an undesirable amount of 
volatility to the 30-day readmission rate. All-cause readmission as a quality measure is 
being extended to ACOs. 29 While it may be reasonable to hold hospitals accountable for 
problems that patients experience within 30 days after discharge, which could reflect 







measure may be less suitable for comparing ACOs. Doing so may significantly impact 
the results and decisions about health care improvement intended by these organizations 
and their payers. For instance, ACOs that disproportionally serve more patients with 
medical and social risk factors that typically lead to frequent hospitalization are likely to 
face financial penalties for high readmission rates. 7–9 This may translate into reluctance 
of some ACOs to care for beneficiaries with high risk of hospitalization and could 
exacerbate existing health disparities.  Excluding high-frequency hospital users from the 
readmission measure could lead payers and ACOs to focus more on patients with lower 
risk of hospitalization who may benefit more from this quality measure. In addition, and 
more importantly, payers and ACOs could redirect resources and efforts to avoiding 
preventable hospitalizations in the first place, improving care transitions and follow-up 
after discharge for the relatively rare people who are high-frequency users of hospitals 
and generate a highly disproportionate share of readmissions. 
1.3 Data Used in The Dissertation 
The first aim of this dissertation used MCBS to develop and validate the new 
CVD risk score that added predictors, such as morbidity burden and functional limitation, 
to those standard CVD Framingham risk score predictors that also could be identified in 
MCBS. The MCBS is a nationally representative probability sample of Medicare 
beneficiaries sponsored by the CMS; it combines information from Medicare claims data 
with in-person survey instruments and provides a comprehensive picture of the use of 
health services, expenditures, and sources of payment for the Medicare population. 10,31 







year for four years, providing three full calendar years of data per respondent. The target 
sample size for an annual MCBS sample is 12,000 beneficiaries. 
The second and third aims of this dissertation used 2015 and 2016 claims and 
enrollment data from MassHealth. In Massachusetts, MassHealth combines both 
Medicaid and the Children’s Health Insurance Program (CHIP). Massachusetts 
established MassHealth in July 1997 to extend Medicaid eligibility to families and 
childless adults whose incomes fall below 200% and 133% of the federal poverty level, 
respectively. Starting in 2018, more than 1.2 million “managed care eligible“ MassHealth 
members may choose their health care from 17 statewide ACOs, two managed care 
organizations, or MassHealth’s primary care clinician (PCC) plan, for which the State 
reimburses providers directly. 32 In 2015, MassHealth was the primary payer for 70.4% of 
its membership and a secondary payer for eligible residents with other primary insurance 
coverage. 
1.4 Summary  
This dissertation illustrates how statistical models can be used with existing 
databases to provide reasonable estimates of risks and health quality outcomes to inform 
health policy. These models are valuable tools which can be applied or adapted by policy 
makers, payers, ACOs, and others to identify, facilitate, and support care of specific 
vulnerable patients to improve their health outcomes. Such modeling is an important step 








A CARDIOVASCULAR DISEASE RISK PREDICTION ALGORITHM FOR USE 










OBJECTIVE: To develop a new CVD risk score, similar to the Framingham Risk Score 
(FRS), that can be calculated using the Medicare Current Beneficiary Survey (MCBS) 
data. 
DATA SOURCES: We studied 17,056 community-dwelling Medicare beneficiaries 
aged 65 years or older without pre-existing CVD using 1999-2009 MCBS data.  
STUDY DESIGN: We developed and validated a new CVD risk score (MCBS-FRS) 
that added predictors, such as morbidity burden and functional limitation, to those 
standard CVD FRS predictors that also could be identified in MCBS. We then compared 
its performance to a modification of the FRS (modified-FRS) that had previously been 
used in MCBS.  
DATA COLLECTION: We obtained risk factors from both survey and claims data. We 
used claims data to derive “CVD event within 3 years” following the FRS definition. 
PRINCIPAL FINDINGS:  Our new MCBS-FRS predicted 3-year CVD events better 
than the modified-FRS. The actual CVD event percentages for those with the highest 5 
and 10 percent of MCBS-FRS predicted risk were 9.1% and 10.1%, while those for the 
modified FRS were 7.5% and 8.1%, respectively. 
CONCLUSIONS: Our new MCBS-FRS risk score can be calculated in MCBS, thereby 









Policy makers and researchers increasingly rely on the Medicare Current 
Beneficiary Survey (MCBS), a nationally representative dataset, for exploring the 
potential benefit of policy changes on health and health care spending. This survey 
contains a wealth of information for health policy-related research on chronic diseases 
and conditions such as cardiovascular disease (CVD). CVD is a highly prevalent chronic 
disease in older Americans – most of whom are Medicare beneficiaries. More than 1 in 3 
adults in the United States currently has CVD; 13 this number will likely increase as the 
U.S. population ages.  CVD is the leading cause of death and a major cause of disability. 
33 Identifying individuals at high risk for CVD-related events, and their substantial effect 
on mortality, disability, and spending is a priority. 
The Framingham Risk Score (FRS) is a powerful tool for classifying individuals 
according to their 10-year CVD risk. It was developed using clinical data collected in the 
Framingham Heart Study. 15 The FRS performs well in terms of discrimination with C 
statistics ranging from 0.76 in men to 0.79 in women. Traditional risk factors in the sex-
specific FRS models for predicting CVD events are age, total cholesterol, high-density 
lipoprotein (HDL) cholesterol, systolic blood pressure (SBP), antihypertensive 
medication use, current smoking, and diabetes status. In addition to these main sex-
specific FRS models, simplified sex-specific FRS models, that use office-based 
predictors that are routinely obtained in primary care and incorporate body mass index 
instead of cholesterol, are also available. They also have a good discriminatory power 







the simplified FRS can be calculated in MCBS because it does not record either 
cholesterol or SBP measures. This makes MCBS less useful for studying distinct CVD 
risk subgroups – what treatments they receive and outcomes they experience.  
We were motivated by our presumption of a need to have a CVD prediction tool 
that can accommodate MCBS; which includes the type of information that is most likely 
to be available to health policy makers and researchers. We sought to develop a proxy for 
the FRS that would enable policy makers and health services researchers to identify high-
risk subpopulations for CVD events using measurements readily available in MCBS. This 
tool is intended for health policy development only, not for helping individual patients 
and clinicians decide on lifestyle modifications and/or CVD therapies. We hypothesized 
that this new CVD risk score, developed on and relying only on data available in the 
MCBS, could potentially improve CVD event prediction and provide insights for 
researchers and policy makers into the potential benefits from targeting health 
interventions to policy-relevant subgroups, such as elderly Medicare beneficiaries, based 
on their risk of developing CVD. 
2.2 Methods 
To our knowledge, only 1 study has attempted to proxy the original FRS using 
MCBS data (in the absence of cholesterol and systolic blood pressure information). 17 
Davidoff and colleagues began with the simplified version of the FRS, which relies on 
systolic blood pressure values, but not cholesterol. They then imputed systolic blood 







for those with treated hypertension. Our purpose was to apply Davidoff’s method to 
compute CVD risk in MCBS and suggest an improvement by adopting a somewhat 
different approach, developing a new CVD Risk score by adding other relevant health 
information from MCBS, rather than imputing clinical measurements that were 
unavailable. We hypothesized that our new (MCBS-FRS) risk score would predict CVD 
events better than the modified FRS used by Davidoff and colleagues. 
2.2.1 Study data 
The MCBS is a nationally representative probability sample of Medicare 
beneficiaries sponsored by the Centers for Medicare and Medicaid Services (CMS); it 
combines information from Medicare claims data with in-person survey instruments and 
provides a comprehensive picture of health services use, expenditures, and sources of 
payment for the Medicare population. 10,31 The MCBS uses a rotating panel design, with 
each patient interviewed 3 times per year for 4 years, providing 3 full calendar years of 
data per respondent. The target sample size for an annual MCBS sample is 12,000 
beneficiaries. 
2.2.2 Study sample 
Our study sample included community-dwelling individuals aged 65 years or 
older from 1999-2009 MCBS data. We excluded patients with a prior history of CVD 
(e.g., myocardial infarction, stroke) as the FRS is designed to predict CVD risk in those 
without pre-existing CVD. We also excluded non-Fee-for-Service (FFS) Medicare 







first year that respondents were observed in the MCBS. Follow-up data (for years 2 and 
3) were used to identify respondents who had a CVD event and to calculate time to CVD 
event, death, or end of observation. To increase our study sample, we also included the 
cohort from 1999 who was in their second year of MCBS in that year, using year 1999 
for their baseline data and year 2000 for potential occurrence of their CVD event.  
Beneficiaries who entered the survey in 2009 had no follow-up data and were 
therefore excluded. As noted, we also excluded MCBS beneficiaries with pre-existing 
CVD in their first year in MCBS. We identified these individuals through claims for 
chronic CVD events using the CVD definition from the Framingham Heart Study 
(coronary heart disease, cerebrovascular disease, peripheral artery disease, and heart 
failure) 34–39 (see Table 2.1).  
2.2.3 Dependent variable 
The CVD outcome was defined during the follow-up period (years 2 and 3 of the 
survey) as at least 1 discharge claim with a principal diagnosis of peripheral artery 
disease or heart failure, or a discharge claim with a diagnosis for MI or stroke in any 
position; or any claim (inpatient or outpatient) with a procedure code for CABG, PTCA, 
carotid endarterectomy, or carotid stenting  34–39 (see Table 2.1).  
2.2.4 Independent variables 
Our CVD risk model included predictors from the original FRS model: age 







smoker, former smoker, current smoker), hypertension status (yes, no), and BMI 
(continuous), as well as additional risk factors that we hypothesized might be related to 
CVD events and were available in MCBS. These included self-reported health status 
(fair/poor, good/excellent), education (more than high school degree, high school degree, 
no high school degree), income ($25,000 or less, more than $25,000), and race/ethnicity 
(Hispanic, non-Hispanic black, non-Hispanic white, other). We also included other 
predictors such as number of activities of daily living (ADL) (range: 0-6), the NAGI 
score (a measure of health status and independence for the elderly, ranging from 0 to 5 
limitations) 40, Medicaid eligibility (yes/no), and morbidity burden (calculated using the 
Diagnostic Cost Group Hierarchical Condition Category (CMS-HCC) classification 
system) .  41 The HCCs are used to calculate a single risk score for each individual based 
on inpatient and outpatient diagnoses from medical claims, with sicker individuals 
receiving higher scores. All independent variables were measured in the beneficiary’s 
baseline year. 
2.2.5 Analyses 
We started with bivariate analyses to assess the relationship between each of the 
above variables and experiencing a CVD event (yes/no). We then used cox proportional 
hazards regression analysis to obtain hazard ratios in the presence of more than 1 
variable. To select the best CVD risk regression model, we used a stepwise approach. We 
started with a full model that included predictors from the original FRS model that are 
available in MCBS (i.e. age, gender, diabetes status, smoking status, hypertension, and 







mentioned above whose P-values were < 0.20 in bivariate analyses (which might become 
statistically significant when combined with other predictors). We used adjusted Wald 
tests to exclude potential predictors that did not improve model fit. After obtaining a final 
main effects model, we tested each predictor that had been dropped initially either in 
bivariate or multivariate analyses and potential interactions to examine whether their 
inclusion/exclusion improved model fit, using the Bayesian information criterion (BIC) 
statistic that penalizes adding variables that do not improve predictions. We tested our 
CVD risk model using 10-fold cross-validation which allowed us to use the whole sample 
for model building. 42,43To assess the performance of our MCBS-FRS and compare it to 
the modified FRS used by Davidoff and colleagues, we calculated C statistics and 
examined calibration plots.  
We also performed sensitivity analyses to assess the robustness of our model with 
a different specification using logistic regression instead of cox proportional hazards 
regression. In addition, we used risk reclassification analysis to assess the performance of 
the regression models. 44,45 With this method, individuals were categorized into CVD risk 
categories (low versus high risk) to identify which model (i.e. the MCBS-FRS or the 
modified FRS) moves individuals who had a CVD event during follow up to the higher 
CVD risk category and those who didn’t experience a CVD event to a lower risk 







We used sampling weights, clustering, and stratification parameters to account for 
the complex survey sample design. Analyses were performed with SAS version 9.3 (SAS 
Institute Inc, Cary, NC) and Stata version 11 (StataCorp, College Station, TX). 
2.3 Results 
Table 2.2 describes the MCBS participants. Fifty-nine percent were female; 58% 
were between 65 and 74 years of age. About five percent (4.87%) of MCBS beneficiaries 
had at least 1 CVD event during follow-up.  
Table 2.3 shows the predictors of CVD retained in our final MCBS-FRS model. 
Each 1-year increase in age was associated with a 5% increase in the risk of a CVD event 
(hazard ratio (HR) =1.05; 95% confidence interval (CI) =1.04-1.06). Females had 23% 
lower risk of having a CVD event compared to men (HR=0.77; 95% CI=0.65-0.91). 
Individuals with diabetes had a 73% higher risk of CVD events than their non-diabetic 
counterparts (HR=1.73; 95% CI=1.47-2.04). Current smokers had twice the rate of a 
CVD event than never smokers (HR=1.87; 95% CI=1.24-1.70). Increases in morbidity 
burden and functional limitation scores were also associated with increases in the 
probability of having a CVD event (HR=1.22; 95% CI=1.10-1.35 and HR=1.12; 95% 
CI=1.06-1.18, respectively). 
The C statistic of the MCBS-FRS was 0.68 (Table 2.3), an improvement of 0.06 
over Davidoff’s modified FRS (C=0.62), and it held up on validation (C = 0.67). More 
importantly, this model was well calibrated and discriminated better in identifying high- 







percentages for the 5 and 10 percent with the highest MCBS-FRS predicted risk were 
9.1% and 10.1%, while those for the modified FRS were 7.5% and 8.1%, respectively 
compared to the actual at random CVD rate of 4.9%.  
Results of the sensitivity analyses are reported in Table A.1 and Table A.2. 
Briefly, the regression coefficients obtained from the logistic regression were very similar 
to those obtained from the cox proportional model.  In addition, the net reclassification 
index for the new MCBS-FRS model was 9.22% which means that the addition of other 
predictors improved the classification for a net of 9 % of beneficiaries. The integrated 
discrimination improvement was 2.35 which suggests an improvement of 235% in the 
discrimination of the MCBS-FRS compared to the modified FRS model. 
2.4 Discussion  
Our goal was to develop a CVD risk score that could be applied to elderly 
Medicare beneficiaries using MCBS data. Our new model had a lower C statistic of 0.68 
compared to C statistics ranging from 0.75 to 0.79 for the original FRS. 15 This was 
expected since the original FRS was based on clinical predictors and was developed on a 
population very different from our MCBS sample. Although its discrimination was 
modest, the C statistic of our risk score was comparable to what was found in a validation 
of a CVD risk score among elderly Medicare enrollees in the REGARDS study, a 
population similar to that of the MCBS. 46,47 Furthermore, our MCBS-FRS outperformed 
a modified version of the FRS that had been used previously with MCBS. 17 Our findings 







specific CVD risk factors: age, gender, diabetes, hypertension, smoking, and BMI. 15,48–51 
We also demonstrated that both measures of total disease burden and functional status 
may partially substitute for unavailable clinical and laboratory information, since they 
also predict future CVD events in the elderly. Indeed, many studies have found that 
morbidity burden and functional status independently contribute to health outcomes in 
elderly patients. 52–55  
Our CVD risk equation allows for a broader range of analyses for addressing 
public health and policy questions than would not be possible using either survey or 
Medicare data alone. 16,31 Not only does the MCBS include a nationally representative 
sample of the US elderly, a high proportion of whom live with chronic conditions, it also 
contains a wealth of information on health outcomes, use of health services, expenditures, 
and sources of payment. 31 The study by Davidoff et al  17 demonstrates the value of 
being able to calculate CVD risk within MCBS. The authors used information on 
beneficiaries with CVD risk to demonstrate the feasibility of a value-based insurance 
design intervention. Value-based insurance design provides financial incentives to 
increase medication adherence in subpopulations where adherence is expected to yield 
particularly high health benefits and long-term cost savings. Davidoff et al found that 
those at higher risk of CVD benefited more from reducing statin co-payments. 17 
Researchers and policy makers will often seek to identify high-risk 
subpopulations to help design efficient population-based health interventions. However, 







needed for calculating the original FRS. Hence, having a good CVD risk predictor that 
can be calculated in rich national databases allows us to estimate the added value of 
targeting interventions to those subpopulations at higher CVD risk. Many studies suggest 
that high-CVD risk patients require interventions that focus on long-term CVD therapies 
and lifestyle changes, including diet, physical activity, and smoking cessation. However, 
several studies have found cost-related underutilization of CVD medications. 56,57 
Appropriately identifying high-risk patients in MCBS, which contains a wealth of 
information on expenditures and payments is valuable in designing interventions that 
focus on reducing out-of-pocket costs, such as value-based insurance designs (which 
many studies have found successful in increasing medication adherence).  58–62 This will 
help increase the proportion of Medicare patients that meet recommended cholesterol and 
blood pressure goals. These well-targeted interventions could also reduce the burden of 
morbidity and mortality associated with CVD and decrease health care spending, since 
CVD is one of the costliest diseases and only about 5% percent of the U.S. population, 
most of which is elderly, is responsible for almost 50% percent of all spending. 63 
The original FRS was developed on a mostly white, homogeneous population of 
individuals aged 30-74 years; hence it may underestimate or overestimate CVD risk in 
other populations, such as individuals with diabetes or other ethnic or racial groups. 64–68 
Our MCBS sample included elderly beneficiaries from all race/ethnicity groups who had 
a much higher risk of CVD and other comorbid conditions than the FRS population. 
When applied to other groups, the original CVD FRS may perform better after 







developing CVD). We were able to improve the ability to predict CVD risk among the 
elderly MCBS beneficiaries by recalibrating the coefficients of established CVD risk 
factors (i.e. gender, diabetes, hypertension, smoking, and BMI). Our method of refitting 
the model in new data (rather than simply using the coefficients of the risk factors in the 
FRS) and including other risk factors, such as morbidity and functional limitation, could 
be replicated to develop specific case-mix modified Framingham scores that may be more 
appropriate for specific databases of specific populations. Our use of cross-validation, 
that allowed the entire sample to be in model development, and sensitivity analyses to 
demonstrate that our new model is robust and reliable, are also worth emulating.  
Our study has limitations. First, we used survey and claims data to develop our 
model. These data are generally thought to be less accurate than the clinical and 
laboratory data used in the original FRS. However, our goal was to build an “FRS-like” 
CVD risk score that relies only on information available in MCBS. Second, the FRS was 
developed using a 10-year follow-up period that was not available for MCBS; our 
MCBS-FRS score predicts CVD events within a 2-year follow-up period.  However, 
identifying individuals at higher CVD risk over a relatively short-time period is also 
important for more timely interventions. Intensive early follow-up and more frequent 
surveillance may improve health and offset future costs associated with avoidable health 
care utilization in this high-risk population. Moreover, even though only about 4.9% of 
our study sample had events with 2 years of follow-up, there were enough CVD events to 
build a stable and credible model.  Furthermore, since MCBS beneficiaries identified by 







easily evaluate their long-term CVD health outcomes. Third, the predictors in the MCBS-
FRS score, except for the HCC disease burden score, were all self-reported, and therefore 
subject to reporting or recall bias. Fourth, we identified CVD outcomes based on claims 
data, which may include “rule-out” diagnosis codes for CVD. 69,70 However, for the 
major CVD events of AMI and stroke we used ICD-9-CM codes that are specific to new 
events (see Table 2.1), mitigating the potential for overestimating CVD outcomes. 
Finally, our results may be representative of the Medicare FFS population only. 
However, complete claims information is required to accurately perform our analyses as 
is usually done in studies of MCBS that are based on analysis of claims data. 
2.5 Conclusion 
We were able to generate a relatively powerful CVD risk score that can be 
computed in MCBS, enhancing the survey’s value for health policy and health services 
research. This CVD risk score, requiring data that is more readily available than what is 
needed to calculate the original FRS, may be similarly effective in helping us learn how 
to reduce CVD events and may allow for a more nuanced examination of the costs and 
benefits of well-targeted health care interventions to improve the health of high-risk 
groups. Future research should externally validate our MCBS-FRS risk score and 
examine its potential to appropriately identify subgroups of subpopulations at high risk of 
CVD for whom targeted interventions may be particularly valuable in preventing heart 







Table 2.1: Diagnosis and procedure codes to identify cardiovascular disease using MCBS claims data 
  ICD-9-CM diagnosis codes ICD-9-CM procedure and CPT codes 
Prevalent CVD*   
Coronary heart 
disease 
410.xx (at least one diagnosis code in one 
inpatient or 2 outpatient/physician claims in 
any dx position)   
CABG: 36.1x, 33510-33536 
PTCA: 00.66, 36.01, 36.02, 36.05, 36.06, 
36.07, 36.09, 92995, 92996, G0290, G0291, 
92980-92984  
(at least one procedure code in any inpatient 
or outpatient/physician claims) 
Peripheral artery 
disease 
440.2 (at least one diagnosis code in one 
inpatient or 2 outpatient/physician claims in 
any dx position) 
 
Heart failure 
428.0, 428.1, 428.9, 404.13, 404.93, 428.20-
428.23, 428.30-428.33, 428.40-428.43 (at 
least one diagnosis code in one inpatient or 





433.xx, 434.xx, 436.xx, 435.xx, 438.xx (at 
least one diagnosis code in one inpatient or 
2 outpatient/physician claims in any dx 
position) 
Carotid endarterectomy or carotid stenting: 
38.12, 00.63, 35301, 37205, 37206, 37215, 
37216 (at least one procedure code in any 
inpatient or outpatient/physician claims) 
 
  
Incident CVD**   
Coronary heart 
disease 
410.xx except 410.x2 in any inpatient 
diagnosis  
CABG: 36.1x, 33510-33536 
PTCA: 00.66, 36.01, 36.02, 36.05, 36.06, 
36.07, 36.09, 92995, 92996, G0290, G0291, 
92980-92984  
(at least one procedure code in any inpatient 








ICD-9-CM diagnosis codes ICD-9-CM procedure and CPT codes 
Peripheral artery 
disease 
440.2 in principal discharge diagnosis and 
admission type is urgent or emergent 
 
Heart failure 428.0, 428.1, 428.9, 404.13, 404.93, 428.20-
428.23, 428.30-428.33, 428.40-428.43 in 




433.x1 or 434.x1 or 436.xx in any inpatient 
diagnosis 
Carotid endarterectomy or carotid stenting: 
38.12, 00.63, 35301, 37205, 37206, 37215, 
37216 (at least one procedure code in any 
inpatient or outpatient/physician claims) 
MCBS= Medicare Current Beneficiary Survey. CVD=cardiovascular disease. ICD-9-CM = International Classification of Diseases, 
Ninth Revision, Clinical Modification. CPT=Current Procedural Terminology. CABG= Coronary artery bypass graft surgery. PTCA 
= Percutaneous transluminal coronary angioplasty. 
* Medicare beneficiaries with prevalent CVD in year 1 of the MCBS were identified and then excluded as the original Framingham 
risk equations are designed to predict CVD risk in those without pre-existing CVD. 









Table 2.2: Baseline characteristics of the study population 
Characteristics of MCBS respondents (%) 




  65-74  58.03 
  75-84   33.49 
  85-plus  8.48 
Race/ethnicity  
  Hispanic 6.09 
  Non-Hispanic black 7.33 
  Non-Hispanic white 81.86 
  Other 4.72 
Gender  
  Female 58.89 
Marital Status  
  Married                      57.23 
Selected health conditions (CVD risk 
factors) 
 
  Diabetes 16.21 
  Hypertension 55.77 
Current smoking  
  Non-smoker 42.90 
  Former smoker 45.20 
  Current smoker 11.90 
BMI categories  
 Underweight 2.15 
 Normal 36.09 
 Obese 22.12 
 Overweight 39.65 
Poor or fair health status (versus 
good/excellent) 
15.43 
HCC score; mean (SD)! 0.80 (0.61) 








Characteristics of MCBS respondents (%) 
Education  
  More than HS degree 43.65 
  HS degree 30.01 
  No HS degree 26.34 
Income  
  $25,000 or less 50.89 
  More than $25,000  49.11 
Source: authors’ calculations using MCBS data. 
MCBS= Medicare Current Beneficiary Survey. HCC: The Centers for Medicare & Medicaid 
Services (CMS) Diagnostic Cost Group Hierarchical Condition Category classification system. 
For some variables, small numbers of respondents had unknown values and are not shown. 
* Fee-for-Service (FFS) community-dwelling beneficiaries first observed in the MCBS between 
1999 and 2008 who did not have claims for pre-existing CVD in baseline year (i.e. coronary 
heart disease, intermittent claudication, congestive heart failure, stroke or transient ischemic 
attack). 
! HCC score measures morbidity burden. The higher the score, the sicker the individual is. 
~ NAGI is a measure of health status and independence for the elderly. NAGI scores range from 
0 to 5 and evaluate a patient’s difficulty in performing 5 activities, including stooping, handling 
small objects, and carrying and lifting weights greater than 10 pounds. The higher the score, the 












Established Framingham score predictors   
Age (per year) 1.05 (1.04-1.06)  
Gender (female) 0.77 (0.65-0.91)  
Diabetes status (yes) 1.73 (1.47-2.04)  
Smoking status   
  Never smoker Reference  
  Former smoker 1.24 (1.04-1.49)  
  Current smoker 1.87 (1.45-2.42)  
Hypertension (yes) 1.45 (1.24-1.70)  
BMI 1.02 (1.00-1.04)  
    
Additional predictors   
HCC morbidity burden score 1.22 (1.10-1.35)  
NAGI score 1.12 (1.06-1.18)  
    
C statistic 67.71   
C statistic after 10-fold cross validation  67.21  
Source: authors’ calculations using MCBS data.  
MCBS= Medicare Current Beneficiary Survey. CVD=cardiovascular disease. HCC: The 
Centers for Medicare & Medicaid Services (CMS) Diagnostic Cost Group Hierarchical 
Condition Category classification system. 
Data used in these analyses were for Fee-for-Service community-dwelling elderly 
beneficiaries first observed in the MCBS between 1999 and 2008 who did not have claims for 
pre-existing CVD in baseline year (i.e. coronary heart disease, intermittent claudication, 
congestive heart failure, stroke or transient ischemic attack). The CVD outcome was defined 
in years 2 or 3 of MCBS by claims for acute CVD event. N(unweighted/weighted) = 
16,867/63,208,832 
This model included the following covariates: age (continuous), gender (female), diabetes 
status (yes), smoking status (never smoker, former smoker, and current smoker), 
hypertension (yes), BMI (continuous), the hierarchical condition category (HCC) morbidity 
burden score (range=0-12), and the NAGI score (measure of health status and independence 
for the elderly, range=0-5).  
The 3-year MCBS-based CVD risk can be calculated by the following equation: 








Xβ = 0.05*(age)-0.27*(female=1) +0.02*(BMI) +0.37*(with hypertension) +0.22*(former 









Figure 2.1: Calibration and discrimination of the new MCBS-based model and the prior modified 
Framingham CVD Risk score in predicting a CVD event among MCBS beneficiaries 
 
MCBS= Medicare Current Beneficiary Survey. CVD=cardiovascular disease. FRS= Framingham Risk Score. 
Markers are deciles of predicted probabilities from each model. Graphs based on 16,867 observations (weighted to 

























Predicted probability of a CVD event







The MCBS-based new model shows better calibration (closer to the 45-degree line) and better discrimination (its 
lowest decile of risk has lower risk (1.1% vs. 1.4%) and its highest decile of risk has higher risk (10.1% vs. 8.1%) 
of CVD events than the modified FRS. 
Our new model is MCBS-based and included the following covariates: age (continuous), gender (female), diabetes 
status (yes), smoking status (never smoker, former smoker, and current smoker), hypertension (yes), BMI 
(continuous), the Centers for Medicare & Medicaid Services Diagnostic Cost Group Hierarchical Condition 
Category (HCC) morbidity burden score (range 0-12), and the NAGI score (measure of health status and 
independence for the elderly, range=0-5). 
The prior model is the modified FRS and was calculated based on the original FRS assuming that MCBS 
respondents with hypertension had an untreated systolic blood pressure of 140mmHg while respondents without 






IMPROVING PERFORMANCE ON HEALTH QUALITY MEASURES BY 
ACCOUNTING FOR MORBIDITY AND SOCIAL DETERMINANTS OF 







IMPORTANCE: Risk-adjusting health quality measures for medical morbidity and 
social determinants of health (SDH) may allow for more accurate comparisons across 
accountable care organizations (ACOs) by more fully accounting for the challenges and 
complexities inherent in caring for vulnerable patients. 
OBJECTIVE: To illustrate the value of risk adjusting quality measures for morbidity 
and SDH factors, using the example of 30-day readmission rates.  
DESIGN, SETTING, AND PARTICIPANTS: Using data from MassHealth, the 
Massachusetts Medicaid and Children's Health Insurance Program, we estimated 
increasingly complex models predicting 30-day readmission using patient demographics, 
medical diagnoses and SDH factors as predictors. We compared these models’ predicted 
rates with actual readmission rates for subgroups of interest for 74,704 hospital stays 
among 42,638 MassHealth managed care eligible members ages 18-64. 
EXPOSURES: Predictors in the diagnosis-based model were: age, sex, and diagnoses 
from claims summarized via CMS’s Hierarchical Condition Category (CMS-HCC) score. 
Our SDH model added predictors for behavioral health issues and for housing instability, 
disability, and neighborhood-level stressors. 
MAIN OUTCOMES AND MEASURES: Model goodness of fit, discriminatory power, 
and predictive ratio: actual 30-day readmission rate divided by model-predicted rate; a 
ratio close to 1 indicates a good fit between actual and predicted outcomes; higher ratios 





RESULTS: We predicted readmission well with only age, sex, and morbidity (C=0.67), 
but better after adding SDH factors (C=0.69). Readmission rates for subgroups with the 
least or most morbidity burden improved from being 51% less and 58% more than 
predicted respectively without adjustment to only 2% more than predicted (i.e.; predictive 
ratio=1.02) after adjusting for age, sex, morbidity, and SDH factors. Observed 
readmission rates for people with serious mental illness and substance abuse were 15% 
and 21% higher than average, respectively. Predictions based on age, sex, morbidity and 
SDH factors brought predictive ratios for these subgroups to 1. Observed rates for 
residents of the most stressed neighborhoods were 8% higher than those in the least 
stressed neighborhoods. Our richest risk adjustment model captured most of this 
difference. Moreover, risk adjustment for morbidity and SDH factors reduced the 37% 
higher than average readmission rates to only 14% more than expected for enrollees who 
used long-term services and supports and fully accounted for the 25% higher than 
average readmission rates for patients with a disability. Risk adjusting for age, sex, 
morbidity and SDH factors reduced differences between the actual readmission rates of 
some pseudo- (realistically simulated) ACO populations and what was expected. 
CONCLUSIONS AND RELEVANCE: Rich risk adjustment models can accurately 
predict readmissions for subgroups with above-average morbidity burden and SDH risk 
factors.  Without risk adjustment, an ACO that cares for beneficiaries with high levels of 
morbidity and SDH risk is likely to be penalized, creating a reluctance to care for such 
patients that could increase health disparities. Not only do payers need to set appropriate 













Accountable care organizations (ACOs) are groups of doctors, hospitals, and 
other health care providers who contract together to provide comprehensive, effective, 
efficient, safe and timely care to their enrolled population. By coordinating  care for their 
members, ACOs also aim to reduce spending.4,5 Payers (e.g. Medicare, Medicaid, private 
insurances) reward ACOs for delivering high quality and efficient health care, providing 
them with an opportunity to share in the savings. 6,71 
Incentives for ACOs are based on measures of health quality for patients overall. 
Payers may choose to focus on a specific subgroup of the population (e.g. those who have 
had a myocardial infarction), to obtain estimates of health quality differences across 
ACOs.  However, a subgroup of patients selected for health quality comparison across 
ACOs may have characteristics that differ between ACOs, undermining the validity of 
the comparison. ACOs that serve a given population may differ on important 
characteristics such as morbidities and social determinants of health (SDH) factors (e.g. 
housing instability, behavioral health issues, disability, and neighborhood-level stressors). 
There is growing evidence that SDH factors play a major role in worse health outcomes 
and higher spending.27,72–79  An ACO that cares for many beneficiaries with morbidity 
burden and social risk factors may have worse performance on ACO quality measures 
and may be less eligible for the shared savings or even responsible to pay penalties to the 
payer when they do not meet a quality benchmark. This may translate into reluctance of 





Risk adjustment of quality measures is an approach intended to “level the playing 
field” by accounting for patient-mix differences among ACOs. The goal of this paper is 
to illustrate the value of adjusting quality measures for age, gender, morbidities and SDH 
factors. We used 30-day readmission rate as an example, as high rates of readmission are 
often taken as a measure of poor quality of care and lowering these rates may serve as a 
good opportunity to reduce health spending 12.  
The Centers for Medicare and Medicaid Services (CMS) has been publicly 
reporting risk-adjusted readmission rates for acute heart failure, pneumonia, and 
myocardial infarction since 2009. 23 However, its risk-adjustment models rely primarily 
on morbidity burden and do not account for other risk factors such as SDH variables. 24–26  
We are aware of two studies that examined the impact of adjustment for social risk 
factors on readmission measure when comparing hospitals.27,28 However, these studies 
found inconsistent results, used limited SDH factors, and focused on Medicare elderly 
population with acute myocardial infarction, heart failure, or pneumonia only. Here, we 
examined all cause adult 30-day readmission rate as a measure of health plan quality in 
an entire Medicaid population, and using both medical and SDH factors, most notably 
serious mental illness and substance use disorder variables. We hypothesized that risk 
adjusting 30-day readmission rates for SDH risk factors in addition to medical morbidity 
may allow for more accurate comparisons across ACOs that appropriately account for the 
challenges and complexities inherent in caring for vulnerable patients. 
3.2 Methods 





We used claims and enrollment data from MassHealth, Massachusetts’ combined 
Medicaid and Children’s Health Insurance Program (CHIP). Massachusetts established 
MassHealth in July 1997 to extend Medicaid eligibility to families and childless adults 
whose incomes fell below 200% and 133% of the federal poverty level, respectively. 
More than 1.2 million MassHealth members are now managed care eligible and may 
choose their health care from 17 statewide ACOs, two managed care organizations, or 
MassHealth’s primary care clinician (PCC) plan, for which the State reimburses 
providers directly.  32 To measure 30-day readmission, we used 2016 data for MassHealth 
managed care eligible enrollees. We assigned enrollees to 17 pseudo- (realistically 
simulated) ACOs which we created by applying MassHealth’s assignment algorithm to 
historic member claims and encounters; all have at least 5,000 members. Actual ACO 
attribution only took effect in 2018. We then assigned the remaining members to the 
other two groups: managed care organization or PCC plan. Because adjustment for the 
readmission measure requires a one-year lookback period for enrollment in Medicaid and 
for measuring morbidity 27,80, 2015 data from the year prior to hospitalization of 
MassHealth beneficiaries were also used. 
3.2.2 Study sample 
We followed strict definitions for eligibility criteria and the measure, based on 
MassHealth ACO Quality Measurement Program designed by the National Committee 
for Quality Assurance (NCQA). 81 NCQA developed the Healthcare Effectiveness Data 
and Information Set (HEDIS) standardized performance measures widely used for 





for this study if they had at least one inpatient stay between January 1st and December 1st, 
2016. We only included hospitalizations for members who were continuously enrolled in 
MassHealth for 365 days (with at most one 45-day gap) prior to the discharge date 
through 30 days after the discharge date. 27,80,81  We excluded hospitalizations for females 
with a principal diagnosis of pregnancy or of a condition originating in the perinatal 
period and for members who had a planned hospital stay (e.g. transplantation, 
chemotherapy, rehabilitation) within 30 days 27,81. Finally, we excluded members 
younger than 18 or older than 64. We allowed members to contribute multiple hospital 
stays to the analyses. Our final study sample included 74,706 unique hospitalizations 
among 42,794 MassHealth members (figure 3.1). We used these hospitalizations 
(hereafter referred to as index hospitalization stays) as the denominator for calculating all 
cause 30-day readmission rates.  
3.2.3 Outcome measure: 
Our dependent variable was 30-day readmission for any diagnosis. For each index 
hospitalization stay, we determined if any of the other subsequent inpatient stays for the 
corresponding member had an admission date within 30 days after the index discharge 
date. For members with multiple hospitalizations during the study period, we included 
each index hospitalization discharge and followed it for 30 days.   
3.2.4 Covariates: 
 We considered three types of covariates.  The first group of variables were age 
and gender which we coded in 12 categories (Table 3.1). The second group of factors 





HCC) model in the year prior to index hospitalization. The CMS-HCC model calculates 
expected costs from age, sex, and diagnoses grouped into condition categories with 
hierarchies 82. When two conditions within the same disease hierarchy co-exist, the 
lower‐ranked diagnosis is ignored.  For instance, a member with claims for both diabetes 
with chronic complications and diabetes without complication is only assigned the 
highest and most costly condition (i.e.; diabetes with chronic complications). While 
originally developed to predict costs, the CMS-HCC model has been widely used to 
measure total morbidity burden. The third group of variables encompassed SDH factors 
including behavioral health issues (i.e. serious mental illness and substance use disorder), 
disability, housing instability, and neighborhood-level stressors. We used SDH factors 
during the measurement year 2016. For members missing 2016 SDH data, which 
constituted about 1.8% of our sample, we included their 2015 SDH information. We used 
two indicators for serious mental illness and substance use disorder based on condition 
categories created with the diagnosis-based Diagnostic Cost Group Hierarchical 
Condition Category software (DxCG-HCC) 41 (Appendix 3.1). MassHealth routinely uses 
the DxCG-HCC software to adjust payments to Medicaid managed care organizations. 
This model is similar to the CMS-HCC model except that it creates indicators for up to 
394 medical condition categories instead of 189. Disability was created based on 
entitlement and qualification for specialized services for mental health or developmental 
disabilities. Housing problems were identified by unstable housing (≥3 addresses within a 
year) and through an international classification of disease (ICD) code indicating 





neighborhood stress score (NSS) derived from a principal components analysis; the NSS 
is calculated at the US Census-block-group level from seven neighbourhood-level 
indicators of economic stress available through the American Community Survey 83 
(Appendix 3.1). 
3.2.5 Statistical analyses  
We compared index hospitalization stays with readmission within 30 days to 
those without using Chi-squared or Student t tests. We then generated model-predicted 
30-day readmission rates (i.e. risk adjusted rates). A model-predicted readmission rate is 
the expected average of readmission for patients with characteristics that are beyond the 
control of an ACO such as age, gender, medical problems, and SDH factors. We 
estimated a series of “nested” (increasingly complex) multivariable logistic models. First, 
we adjusted the readmission rates for age, sex, and morbidity burden only. Second, we 
added the behavioral health variables: serious mental illness and substance use disorder. 
Third, we added the remaining SDH factors (i.e. disability, housing problem, NSS). To 
compare the goodness of fit among the models, we used the Akaike’s information 
criterion (AIC) that penalizes adding variables that do not improve predictions.  To assess 
the discriminatory power of the models, we calculated the C statistic representing the area 
under the receiver operating characteristic curve. A value of 0.5 indicates no ability to 
discriminate; higher values close to 1.0 indicate a better model fit. Finally, we compared 
the risk adjustment models, examining how well they fit race-, morbidity-, and SDH-





day readmission rate divided by its average model-predicted (expected) rate. A predictive 
ratio closer to 1 indicates accurate prediction with higher ratios considered worse.  
We used hierarchical generalized linear models to account for clustering of index 
hospitalizations within patients and patients within ACOs. Clustering may result in 
potential violation of the assumption of independence required in many statistical tests 
and generalized linear models. Variation in hospital readmission may be smaller between 
hospitalizations attributed to the same patient or same ACO than between hospitalizations 
attributed to different patients or different ACOs. Controlling for clustering leads to more 
precise estimates. All analyses were carried out using the SAS package version 9.4 (SAS 
Institute, Cary NC, USA) and Stata software version 12 (Stata Corporation., College 
Station, TX, USA). 
3.3 Results 
 Index hospitalization stays with 30-day readmission significantly differed from 
those without readmission on all demographic, morbidity, and SDH variables (Table 3.1).  
For instance, discharges from index hospitalizations that were followed by readmission 
within 30 days were more likely among older male patients (35.8% vs 30.30% compared 
to those without readmission) and among sicker patients (mean morbidity scores of 3.5, 
SD=2.5 vs 2.4, SD=2.0).  Index hospitalizations with 30-day readmission were more 
likely among patients with serious mental illness (80.7% vs 66.6% for those without 
readmission) and substance use disorder (74.4% vs 57.7%). Index hospitalizations with 
30-day readmission were also more likely among patients with housing problems (32.9% 





Table 3.2 shows that we can predict readmission well with only age, sex, and 
morbidity in risk adjustment models (AIC=69,776, C=0.67), but better with the addition 
of behavioral health predictors and other SDH factors (AIC=69,029, C=0.69). Predictive 
ratios were closer to 1 (i.e.; predicted readmission rates were closer to actual rates) as we 
moved from the non-adjusted model to the richer risk adjustment model with age, sex, 
morbidity, and SDH factors as predictors. For example, the actual readmission rate for 
patients with housing problems was 23% higher than average without adjustment (i.e.; 
predictive ratio=1.23), 16% higher after adjusting the predicted rate for age, sex, and 
morbidity, 12% higher with additional adjustment for behavioral health issues, and equal 
to predicted after adjustment for age, sex, medical, and all SDH factors. 
The expected 30-day readmission rates predicted by each risk adjustment model, 
were generally close to actual rates for racial subgroups (Table 3.2). However, expected 
rates were not close to actual rates for subgroups with the least or most morbidity burden, 
for whom rates improved from being 51% less and 58% more than predicted respectively 
without adjustment to only 2% more than predicted after adjusting for age, sex, 
morbidity, behavioral health issues, and other SDH factors. Readmission rates for people 
with serious mental illness and substance abuse were 15% and 21% higher than average 
without adjustment, respectively. Taking into account age, sex, morbidity and all SDH 
factors corrected predicted readmission rates, yielding predictive ratios equal to 1. 
Readmission rates for residents of the most stressed neighborhoods were 8% higher than 
those in the least stressed neighborhoods (22.7/21.0 = 1.08). Our richest risk adjustment 





and SDH factors reduced the 37% higher than expected readmission rates to only 14% for 
enrollees who used long-term services and supports and eliminated the 25% higher than 
expected readmission rates for patients with a disability. Table 3.2 also shows that risk 
adjusting for age, sex, morbidity and SDH factors reduced differences between the actual 
readmission rates of some pseudo- (realistically simulated) ACO populations and what 
was expected. 
3.4 Discussion 
We risk adjusted 30-day readmission measure for age, sex, morbidity burden and 
SDH factors improving goodness of fit and discriminatory power overall and 
dramatically improving the match between actual and expected readmission rates for 
several subgroups of vulnerable MassHealth managed care eligible members. These 
members, whose readmission rates are much higher than expected before risk adjustment, 
are patients who have high morbidity levels, disability, behavioral health problems, and 
housing issues. Our results are consistent with prior studies demonstrating the association 
between SDH factors and readmission. 7–12 Moreover, our findings are analogous and 
consistent with results of a payment model that adjusted for SDH variables in addition to 
medical diagnoses and which was implemented by MassHealth in 2016 to meet the needs 
of socially disadvantaged beneficiaries83.  
This study illustrates how a quality measure that does not account for age, sex, 
morbidity burden, and SDH factors can seriously affect some vulnerable populations. 
This may generate unfair financial stress for ACOs that disproportionally serve and care 





responsible to pay a portion of losses to payers when they fail to meet a quality threshold. 
7,8 This systematic penalty may make ACOs reluctant to care for such beneficiaries, 
possibly leading to increased health disparities. Hence, risk adjusting quality measures 
may protect ACOs that disproportionally serve medically and socially complex patients 
from unfair quality penalties that would otherwise make them ineligible for shared 
savings. These extra dollars may, for instance, help design and implement interventions 
to facilitate and improve care for vulnerable populations; this may incentivize ACOs to 
overcome barriers to better health outcomes for high-risk populations. 
Health quality models such as ours may be used by policy makers, payers, and 
ACOs to identify morbidity and SDH subgroups such as those defined in this study or 
other potential subgroups with issues requiring distinct programs to reduce disparities. 
Payers may want to examine quality measures for subgroups of patients based on SDH 
factors in addition to calculating a single measure for all members or subsets with 
specific medical conditions. They may choose to set different quality improvement 
standards for subgroups of vulnerable patients for whom caring may be complex and 
difficult, and for whom current outcomes are worse than average. Moreover, payers may 
need to provide ACOs additional special rewards and support as incentives to enroll and 
care for medically and socially complex subpopulations. Supporting ACOs to collaborate 
with social services and community associations may also facilitate and improve access 
to and engagement with health care for these vulnerable patients. For instance, payers 
may give ACOs that serve patients from distressed neighborhoods extra resources to 





linking medically complex patients to community health workers to help them address 
the main causes of their recurrent health issues. 83 Programs that reward improvements in 
heath quality for disadvantaged groups and payment arrangements that support ACO 
development in disadvantaged communities may be necessary since the most vulnerable 
members remained underrepresented in managed care programs. 83 The goal is to reduce 
health disparities while avoiding inappropriately penalizing ACOs that disproportionally 
serve medically and socially complex patients. 
This study has limitations. First, it seems likely that a model that could account 
for additional important social risk factors, such as social support, health literacy, English 
proficiency, and functional status – would perform better 24,25,84. However, we could use 
only readily available predictors. MassHealth may need to work with ACOs and other 
state entities, such as social and housing services, to obtain other factors to augment their 
data. Having additional factors available in the future will add value to analyses that 
address important health policy questions. Second, to improve the precision of our 
prediction models, we controlled for clustering of hospitalizations within patients and 
patients within ACOs and other settings that we assigned based on an algorithmic 
attribution. However, our ACO attribution may differ from actual member attribution or 
assignment of ACOs that went into effect later in 2018.  Finally, our study was limited by 
a geographically constrained population that included MassHealth members only. 
Priorities and support given to advance coverage, access, health outcomes, and efficiency 
goals may differ from state to state. Hence, our findings may not generalize to other 





Despite these limitations, this is the first study to risk-adjust a quality measure 
using a broader group of SDH factors, most notably health behavioral variables. In 
addition, this study used MassHealth, a large statewide healthcare database. In 2015, 
MassHealth was the primary payer for 70.4% of its membership and a secondary payer 
for eligible residents with other primary insurance coverage, which represented 28.3% of 
total MassHealth membership. We were able to identify medically and socially 
disadvantaged Massachusetts Medicaid beneficiaries whose needs should be addressed 
immediately to improve health quality overall, reduce health disparities, and decrease 
spending.  
3.5 Conclusion 
Our comprehensive medical and SDH-based risk adjustment model development 
can be replicated by others to facilitate and support care of vulnerable patients by 
improving hospital readmission and other quality measures. Such modeling is an 









                                                                                                                               
                                                                                                                            
































Figure 3.1: Study population flow chart, hospital stays between Jan 1st and Dec 1st, 2016 
among MassHealth managed care eligible enrollees
125,984 Index Hospital stays  
of 82,712 MassHealth beneficiaries  
    
Final study sample  
74,706 stays 
of 42,794 members 
18,980 stays with a principal dx of 
pregnancy or of a condition 
originating in the perinatal period 
(17,649 Females) 
528 planned hospital stays within 
30 days (346 members) 
10,026 stays (for 7,198 members younger 
than 18 or older than 64) 
104,240 stays  
of 67,149 Beneficiaries with continuous enrollment within 365 
days (with at most one gap) prior to the Index Discharge Date 
through 30 days after the Index Discharge Date 







Table 3.1: Baseline Characteristics of index Hospital Discharges by 30-Day Re-admission  
  Readmitted Not Readmitted P- value a 
  #  % #  %   
Total 16,485 22.1% 58,221 77.9%  





  18-24 Female 748 4.5% 2,720 4.7%  
  25-34 Female 1,699 10.3% 6,276 10.8%  
  35-44 Female 1,436 8.7% 5,828 10.0%  
  45-54 Female 1,902 11.5% 7,628 13.1%  
  55-59 Female 977 5.9% 3,806 6.5%  
  60-64 Female 754 4.6% 3,329 5.7%  
  18-24 Male 666 4.0% 2,488 4.3%  
  25-34 Male 1,712 10.4% 5,602 9.6%  
  35-44 Male 1,897 11.5% 5,463 9.4%  
  45-54 Male 2,613 15.9% 7,742 13.3%  
  55-59 Male 1,178 7.1% 3,975 6.8%  






  White/Non-Hispanic 8,074 49.0% 28,345 48.7%  
  Black/Non-Hispanic 1,384 8.4% 5,155 8.9%  
  Hispanic 1,003 6.1% 4,240 7.3%  
  Other non-Hispanic 284 1.7% 1,385 2.4%  
  Missing/unknown 5,740 34.8% 19,096 32.8%  
      
HCC morbidity burden, mean (SD) 3.5 2.5 2.4 2.0 0.000 
      
Behavioral health      
  Serious mental illness 13,306 80.7% 38,779 66.6% 0.000 







      
      
  Readmitted Not Readmitted P- value a 
  #  % #  %   
Any LTSS use 7,593 46.1% 17,430 29.9% 0.000 

















  Least stressed neighborhood quartile 3,908 23.7% 14,734 25.3%  
  Most stressed neighborhood quartile 4,230 25.7% 14,426 24.8%   
Source: Authors’ calculations using data on 74,706 hospitalizations between Jan 1st and Dec 1st, 2016 of 42,794 MassHealth 
managed care eligible adult members. 
Abbreviations: HCC, the CMS-HCC diagnosis-based Hierarchical Condition Category; SD, standard deviation; LTSS, long-
term services and supports. 
a P values based on Chi-squared and Student t tests. 
b based on entitlement and qualification for specialized services for mental health or developmental disabilities in 2016. 
c defined as 3+ distinct addresses or homelessness (Z59.0) on claims or encounter records during 2016. 







Table 3.2: Rates and Predictive Ratios for models predicting 30-day readmission among subpopulations a 
 
Subgroups/Models 








Risk adjustment for age, 






(1) + serious mental illness 





(2) + disability, neighborhood- 




    
Predictive    
















All 74,706 100.0% 22.1% 1.00 22.1% 1.00 22.1% 1.00 22.1% 1.00 
Race/ethnicity subgroups                
   Black 6,539 8.8% 21.2% 0.96 21.9% 0.97 21.1% 1.00 21.5% 0.99 
   White 36,419 48.7% 22.2% 1.00 22.1% 1.00 22.5% 0.99 22.4% 0.99 
   Hispanic 5,243 7.0% 19.1% 0.86 22.1% 0.86 21.6% 0.88 22.2% 0.86 
   Other 1,669 2.2% 17.0% 0.77 19.7% 0.86 17.7% 0.96 17.4% 0.98 
   Missing Unknown 24,836 33.2% 23.1% 1.05 22.2% 1.04 22.1% 1.05 22.0% 1.05 
Any LTSS use 25,023 33.5% 30.3% 1.37 26.5% 1.14 26.3% 1.15 26.6% 1.14 
Disability 25,682 34.4% 27.7% 1.25 24.5% 1.13 25.1% 1.10 27.7% 1.00 
                 
Morbidity burden                
 Lowest morbidity burden 
quartile 
19,008 25.4% 11.3% 0.51 11.6% 0.97 11.2% 1.01 11.1% 1.02 
 Highest morbidity 
burden quartile 
18,681 25.0% 35.0% 1.58 34.9% 1.00 35.0% 1.00 34.4% 1.02 
















Risk adjustment for age, 
sex, and morbidity 
(1) 
 
(1) + serious mental illness 
and substance use disorder 
(2) 
 
(2) + disability, neighborhood- 
level stressors, and housing 
issues 
 
    
Predictive    
















Behavioral health                
  Serious mental illness 52,085 69.7% 25.5% 1.15 23.2% 1.10 25.5% 1.00 25.6% 1.00 
  Substance use disorder 45,837 61.4% 26.7% 1.21 24.2% 1.10 26.7% 1.00 26.7% 1.00 
Housing                
  Housing problem 20,010 26.8% 27.1% 1.23 23.4% 1.16 24.3% 1.12 27.1% 1.00 
  Least stressed 
neighborhood quartile d 
18,642 25.0% 21.0% 0.95 21.5% 0.98 21.4% 0.98 20.9% 1.00 
  Most stressed 
neighborhood quartile 
18,656 25.0% 22.7% 1.03 22.6% 1.00 22.7% 1.00 22.9% 0.99 
Select pseudo ACOs e                  
  ACO_1 1,800-8,000 ***** 23.5% 1.06 21.6% 1.09 22.2% 1.06 22.6% 1.04 
  ACO_2 1,800-8,000 ***** 22.3% 1.01 22.2% 1.01 22.4% 1.00 22.2% 1.00 
  ACO_3 >8,000 ***** 24.6% 1.11 23.0% 1.07 23.5% 1.05 23.9% 1.03 
  ACO_4 >8,000 ***** 24.3% 1.10 22.2% 1.09 22.7% 1.07 22.8% 1.07 
Model performance             
  AIC     71,908 69,776 69,208 69,029 
  C statistic*100       50.00 66.65 68.26 68.78 
Source: Authors’ calculations using data on 74,706 hospitalizations between Jan 1st and Dec 1st, 2016 of 42,794 MassHealth 
managed care eligible adult members. 
Abbreviations: AIC, Akaike’s information criterion; LTSS, long-term services and supports; ACO, accountable care organization 
a Estimates are based on hierarchical generalized linear models with a logit link and a binomial distribution 
b Predictive ratio is the group’s average actual (observed) 30-day readmission rate divided by its average model-predicted 
(expected) rate. Ratios close to 1 reflect good model fit.  







d Neighborhood stress measure summarizes seven neighborhood-level indicators of economic stress using US Census block 
groups. 
e Pseudo ACOs are created by applying MassHealth’s assignment algorithm to historic member claims and encounters. Actual 
ACO attribution only took effect in 2018; numbers categorized or masked for confidentiality. 
Morbidity burden is measured using the CMS-HCC diagnosis-based Hierarchical Condition Category score. 
Disability status is Medicaid entitlement for disability or qualification for specialized services for mental health or developmental 
disabilities in 2016. 







SHOULD HIGH-FREQUENCY HOSPITAL USERS BE EXCLUDED FROM 30-







BACKGROUND: Thirty-day readmission rate is a popular metric for measuring the 
performance of hospitals, health plans, and accountable care organizations (ACOs). Like 
other quality measures, it is based on clinical guidelines that apply to the general 
population or specified subgroups. However, even in a targeted subpopulation, a few 
patients who frequently use hospitals may add unwanted volatility to a readmission 
measure. 
OBJECTIVES: We sought to describe the characteristics of MassHealth members who 
are high-frequency hospital users (with 4 or more hospital visits per year) and to assess 
the impact of their inclusion or exclusion on 30-day readmission. 
METHODS: We studied managed care eligible MassHealth patients with at least one 
acute inpatient stay during 2016. We assessed demographics, morbidity burden, and 
social determinant of health factors for both high-frequency hospital users and low-
frequency users. We then evaluated the extent to which the inclusion or exclusion of 
high-frequency users from the 30-day readmission measure changes its rate and its 
variance.  
RESULTS: Of the 42,794 unique patients with at least one acute hospitalization in 2016, 
only 8.7% were high-frequency hospital users, contributing 30.2% of all hospital visits. 
These patients were more likely to be male (77.1% vs. 50.0%), 35 years or older (72.1% 
vs. 69.7%), with high morbidity burden (CMS-HCC score of 3.3 (SD=2.2) vs. 1.9 





health factors (33.1% with housing problems, 44.1% disabled, 83.2% with serious mental 
illness, 77.1% with substance abuse disorder, and 25.3% living in most stressed 
neighborhoods compared to 22.0%, 27.3%, 60.2%, 50.0%, 24.5% for low-frequency 
users of hospitals respectively). Their readmission rate was 50.7% compared to 9.7% for 
other patients. These patients also contributed 72.0% of the variance in 30-day 
readmission which is due to clustering of hospitalizations within patients.  
CONCLUSIONS: Despite their small proportion, high-frequency hospital users have a 
huge impact on 30-readmission rates. Excluding these patients from readmission and 
other quality measures could benefit medically and socially complex patients and the 







Thirty-day readmission rate is commonly used to measure and compare the 
performance of hospitals and to encourage more attentive post-acute care and reduced 
health care spending. Under the Affordable Care Act, the Centers for Medicare and 
Medicaid  Services (CMS) penalizes hospitals for excessive unplanned readmissions9. 
Like other quality measures, 30-day readmission is based on clinical guidelines that apply 
to the general population or specified subgroups. The CMS has been publicly reporting 
readmission rates for acute heart failure, pneumonia, and myocardial infarction for 
several years23. However, even among targeted subpopulations, such as patients 
hospitalized for these conditions, a small subgroup of individuals who frequently use 
hospitals may add undesirable amounts of volatility to the 30-day readmission rate.  
All-cause unplanned readmission as a quality measure is being extended to 
accountable care organizations (ACOs)29 . While it may be reasonable to hold hospitals 
accountable for problems that patients experience within 30 days after discharge, which 
could reflect poor hospital care or a too-early transition to an outpatient setting30, a 
readmission measure may be less suitable for comparing ACOs. Doing so may 
significantly impact the results and decisions about health care improvement intended by 
these organizations and their payers. For instance, ACOs that disproportionally serve 
more patients with medical and social risk factors that typically lead to frequent 
hospitalization may face financial penalties for high readmission rates. This may translate 
into reluctance of some ACOs to care for beneficiaries with high risk of hospitalization 





from the readmission measure, could lead payers and ACOs to focus more on patients 
with lower risk of hospitalization who may benefit more from this quality measure. In 
addition, and more importantly, payers and ACOs could redirect resources and efforts to 
avoiding preventable hospitalizations in the first place, improving care transitions, and 
bettering follow-up after discharge for the relatively few high-frequency users of 
hospitals, who are responsible for a disproportionate share of readmissions. 
We sought to describe the characteristics of MassHealth beneficiaries who are 
high-frequency hospital users (who visit the hospitals 4 or more times per year) and their 
patterns of hospital use and readmissions. We also evaluated the extent to which the 
inclusion or exclusion of high-frequency users from the 30-day readmission measure 
changes its rate and its variance. 
4.2 Methods 
4.2.1 Study data 
We used claims and enrollment data from MassHealth, Massachusetts’ combined 
Medicaid and Children’s Health Insurance Program (CHIP). Massachusetts established 
MassHealth in July 1997 to extend Medicaid eligibility to families and childless adults 
whose incomes fell below 200% and 133% of the federal poverty level, respectively. 
More than 1.2 million MassHealth members are now managed care eligible and may 
choose their health care from 17 statewide ACOs, two managed care organizations, or 
MassHealth’s primary care clinician (PCC) plan, for which the State reimburses 





managed care eligible enrollees. We assigned enrollees to 17 pseudo- (realistically 
simulated) ACOs which we created by applying MassHealth’s assignment algorithm to 
historic member claims and encounters; all have at least 5,000 members. Actual ACO 
attribution only took effect in 2018. We then assigned the remaining members to the 
other two groups: managed care organization or PCC plan. Because adjustment for the 
readmission measure requires a one-year lookback period for enrollment in Medicaid and 
for measuring morbidity 27,80, 2015 data from the year prior to hospitalization of 
MassHealth beneficiaries were also used.  
4.2.2 Study sample 
 We followed strict definitions for eligibility criteria and the 30-day readmission 
measurement.  based on MassHealth ACO Quality Measurement Program designed by 
the National Committee for Quality Assurance (NCQA). 81 NCQA developed the 
Healthcare Effectiveness Data and Information Set (HEDIS) standardized performance 
measures widely used for evaluating quality of care delivered by health care 
organizations. Members were eligible for this study if they had at least one inpatient stay 
between January 1st and December 1st, 2016. We only included hospitalizations for 
members who were continuously enrolled in MassHealth for 365 days (with at most one 
45-day gap) prior to the discharge date through 30 days after the discharge date. 27,80,81  
We excluded hospitalizations for females with a principal diagnosis of pregnancy or of a 
condition originating in the perinatal period and for members who had a planned hospital 
stay (e.g. transplantation, chemotherapy, rehabilitation) within 30 days 27,81. Finally, we 





multiple hospital stays to the analyses. Our final study sample included 74,706 unique 
hospitalizations among 42,794 MassHealth members (figure 3.1). We used these 
hospitalizations (hereafter referred to as index hospitalization stays) as the denominator 
for calculating all cause 30-day readmission rates. 
4.2.3 Outcome measures: 
Our two main outcome measures were hospitalization (as defined and described 
above) and 30-day readmission for any diagnosis. For each index hospitalization stay, we 
determined if any other acute inpatient stay for that member had an admission date within 
30 days after the index discharge date. For members with multiple hospitalizations during 
the study period, we included each index hospitalization discharge and followed it for 30 
days.  
4.2.4 Covariates: 
 We considered three types of covariates.  The first group of variables were age 
and gender. The second group of factors measured morbidity burden using the CMS’s 
Hierarchical Condition Category (CMS-HCC) model in the year prior to index 
hospitalization. The CMS-HCC model calculates expected costs from age, sex, and 
diagnoses grouped into condition categories with hierarchies 82. When two conditions 
within the same disease hierarchy co-exist, the lower‐ranked diagnosis is ignored.  For 
instance, a member with claims for both diabetes with chronic complications and diabetes 
without complication is only assigned the highest and most costly condition (i.e.; diabetes 
with chronic complications). While originally developed to predict costs, the CMS-HCC 





variables encompassed SDH factors including behavioral health issues (i.e. serious 
mental illness and substance use disorder), disability, housing instability, and 
neighborhood-level stressors. We used SDH factors during the measurement year 2016. 
For members missing 2016 SDH data, which constituted about 1.8% of our sample, we 
included their 2015 SDH information. We used two indicators for serious mental illness 
and substance use disorder based on condition categories created with the diagnosis-
based Diagnostic Cost Group Hierarchical Condition Category software (DxCG-HCC) 41 
(Appendix 3.1). MassHealth routinely uses the DxCG-HCC software to adjust payments 
to Medicaid managed care organizations. This model is similar to the CMS-HCC model 
except that it creates indicators for up to 394 medical condition categories instead of 189. 
Disability was created based on entitlement and qualification for specialized services for 
mental health or developmental disabilities. Housing problems were identified by 
unstable housing (≥3 addresses within a year) and through an international classification 
of disease (ICD) code indicating homelessness (Appendix 3.1). Neighborhood-level 
stressors were summarised by a neighborhood stress score (NSS) derived from a principal 
components analysis; the NSS is calculated at the US Census-block-group level from 
seven neighbourhood-level indicators of economic stress available through the American 
Community Survey 83 (Appendix 3.1). 
4.2.5 Statistical analyses 
First, we used Chi-squared and Student t tests to assess the association between 
each covariate and high hospitalization use (4 or more eligible hospitalizations in 2016). 





Third, we investigated the effect of including/excluding high-frequency users from the 
30-day readmission measure on its variance. 
Because some patients have multiple hospitalizations and each ACO serves a 
unique set of patients, we used hierarchical generalized linear models. Clustering may 
result in potential violation of the assumption of independence required in many 
statistical tests and generalized linear models. Variation in hospital readmission may be 
smaller between hospitalizations attributed to the same patient or same ACO than 
between hospitalizations attributed to different patients or different ACOs. Controlling 
for clustering leads to more precise estimates. We estimated the intraclass correlation 
coefficient (ICC), which is the ratio of the between-cluster variance that is accounted for 
by clustering to the total variance in 30-day readmission. We attributed the variance in 
30-day readmissions to three levels: ACOs, patients, and hospitalizations. 
Hospitalization-level ICC is the residual variance after the ACO level and patient level 
variances have been accounted for. We ran 2 logistic models with random effects only 
(unadjusted) to estimate the total variance at each of the 2 ACO- and patient-levels. The 
first model included all patients while the second excluded high-frequency hospital users. 
Finally, to assess whether some of the variance at the ACO- and patient-levels can be 
attributed to patient characteristics, we re-ran these 2 models adding the fixed effects for 
12 age/sex categories, morbidity, serious mental illness, substance use disorder, 
disability, neighborhood- level stressors, and housing issues 85. All analyses were carried 
out using the SAS package version 9.4 (SAS Institute, Cary NC, USA) and Stata software 






Of the 42,794 unique patients with at least one acute hospitalization in 2016, only 
3,728 (8.7%) were high-frequency hospital users, contributing 22,586 (30.2%) of all 
hospital visits (Table 4.1). These patients were more likely to be male (77.1% vs. 50.0%), 
35 years or older (72.1% vs. 69.7%), with high morbidity burden (CMS-HCC score of 
3.3 (SD=2.2) vs. 1.9 (SD=1.5) for low-frequency users of hospitals), and with significant 
social determinant of health factors (33.1% with housing problems, 44.1% disabled, 
83.2% with serious mental illness, 77.1% with substance abuse disorder, and 25.3% 
living in most stressed neighborhoods compared to 22.0%, 27.3%, 60.2%, 50.0%, 24.5% 
for low-frequency users of hospitals respectively).  
The readmission rate for high-frequency hospital users was 50.7% in contrast to 
9.7% for other patients. By excluding high-frequency hospital users from the readmission 
measure, the overall readmission rate was cut by more than half (9.7% vs. 22.1% 
including all patients) (data not shown).   
Table 4.2 provides the composition of variance in 30-day readmission attributed 
to clustering at the ACO level and at the patient level: 35.0% of the total variance in 30-
day readmission was between patients; multiple hospitalizations within one patient were 
more similar than among random patients. However, this estimate dropped to only 9.8% 
after excluding high-frequency users, suggesting that this group of patients is responsible 
for 72.0% of the variance in 30-day readmission which is due to nesting of 
hospitalizations within patients ([35.0 -9.8]/ 35.0). On the other hand, the proportion of 





level (ICC of 0.3% or less before or after excluding high-frequency users). Furthermore, 
whether we excluded high-frequency hospital users from the 30-day readmission 
measure, ICC was always lower in the adjusted models than in the unadjusted models. 
That is, risk adjusting 30-day readmission by taking into account patient characteristics 
also decreases variability in this measure, making it more stable. 
4.4 Discussion 
We found that a small group of MassHealth beneficiaries are responsible for 
disproportionate hospitalization use and have an outsized effect on 30-day readmission 
and its variability. These beneficiaries are sicker than other patients, with significant 
mental illness, drug dependence abuse, and housing issues. A better understanding of 
which patients may be at risk for frequent hospital use is important because many of their 
initial hospitalizations could perhaps be prevented through more effective and targeted 
interventions. Moreover, a better understanding of which patients are at highest 
likelihood of readmission after hospitalization may enable clinicians, ACOS, and policy 
makers to focus efforts on patients who will benefit the most from heath interventions 
after hospitalization.  
The 30-day readmission measure may have less utility for judging ACOs than 
hospitals. ACOs that disproportionally serve many high-frequency hospital users may be 
disproportionately affected by facing penalties for having high readmission rates. 7,8 On 
the contrary, these ACOs are the ones that are in need of extra money to spend on caring 
for the medically and socially complex subpopulations they serve who use hospitals more 





frequency users from the 30-day readmission measure. This will decrease the 
heterogeneity of the population targeted by the readmission measure to keep only patients 
who are most likely to benefit from its improvement. Moreover, given finite resources, it 
is reasonable for ACOs to focus efforts on enrollees with greater likelihood of 
hospitalization and readmission to improve health quality overall and reduce spending. 
First, ACOs may focus more on characterizing which hospitalizations may be preventable 
and on designing health programs that enroll and most benefit these high-risk patients 
such as individualized patient care plans, coordinated care, and improvement of discharge 
summaries. 86–88 Second, designing and implementing comprehensive social programs for 
the high-frequency hospital use subpopulation are particularly beneficial given this 
population’s prevalence of mental illness, drug abuse, and housing issues. 89,90 
This study has limitations. First, it seems likely that a model that could account 
for additional important social risk factors, such as social support, health literacy, English 
proficiency, and functional status – would perform better 24,25,84. However, we could use 
only readily available predictors. MassHealth may need to work with ACOs and other 
state entities, such as social and housing services, to obtain other factors to augment their 
data. Having additional factors available in the future will add value to analyses that 
address important health policy questions. Second, to improve the precision of our 
prediction models, we controlled for clustering of hospitalizations within patients and 
patients within ACOs and other settings that we assigned based on an algorithmic 
attribution. However, our ACO attribution may differ from actual member attribution or 





a geographically constrained population that included MassHealth members only. 
Priorities and support given to advance coverage, access, health outcomes, and efficiency 
goals may differ from state to state. Hence, our findings may not generalize to other 
states, programs, and populations. 
4.5 Conclusion 
 High-frequency hospital users have many medical morbidities and significant 
psychiatric, substance abuse, and housing problems. Despite their small numbers, they 
exert a large influence on 30-readmission rates, this raises questions about how to fairly 
judge readmissions for them and the ACOs that disproportionally serve them. This study 
suggests that it might be wise to exclude high-frequency users from the re-admission 













P- value a 
  #  % #  %   
Total number of enrollees (%) 3,728 100.0% 39,066 100.0%   
Total number of hospitalizations (%) 22,586 100.0% 52,120 100.0%   
          
  Male 2,873 77.1% 19,533 50.0% 0.000 
           
Category of age          
  18-34 1,041 27.9% 11,815 30.2% 0.000 
  35-54  1,829 49.1% 17,427 44.6%   
  55-64 858 23.0% 9,824 25.1%   
           
Race/Ethnicity          
  White/Non-Hispanic 1,817 48.7% 18,920 48.4% 0.000 
  Black/Non-Hispanic 337 9.0% 3,469 8.9%   
  Hispanic 219 5.9% 2,988 7.6%   
  Other non-Hispanic 60 1.6% 1,035 2.6%   
  Missing/unknown 1,295 34.7% 12,654 32.4%   
           
HCC morbidity burden, mean (SD) 3.3 2.2 1.9 1.5 0.000 
           
Housing problems b 1,233 33.1% 8,614 22.0% 0.000 
           
Disability c 1,643 44.1% 10,682 27.3% 0.000 







     
     
  >= 4        1-3  
 hospitalizations hospitalizations P- value a 
 # % # %  
Serious mental illness 3,103 83.2% 23,513 60.2% 0.000 
           
Substance use disorder 2,873 77.1% 19,533 50.0% 0.000 
           
Any LTSS use 1,769 47.5% 9,265 23.7% 0.000 
           
Neighborhood stress score quartile d          
  Least stressed neighborhood quartile 891 23.9% 10,063 25.8% 0.002 
  Most stressed neighborhood quartile 942 25.3% 9,586 24.5%  
Source: Authors’ calculations using data on 74,706 hospitalizations between Jan 1st and Dec 1st, 2016 of 42,794 
MassHealth managed care eligible adult members. 
Abbreviations: HCC, Morbidity burden measured using the CMS-HCC diagnosis-based Hierarchical Condition Category 
score; LTSS, long-term services and supports; SD, standard deviation. 
a Chi-square or Student t test. 
b Housing problem is defined as 3+ distinct addresses or homelessness (Z59.0) on claims or encounter records during 
2016. 
c Disability status is Medicaid entitlement for disability or qualification for specialized services for mental health or 
developmental disabilities in 2016. 










Table 4.2: Variance decomposition statistics for 30-day readmission 
  Patient-level ICC Pseudo ACO a-level ICC 
Unadjusted   
  All enrollees 35.0% (33.7%-36.3%) 0.2% (0.1%-0.7%) 
  Low-frequency hospital users only 9.8% (7.5%-12.9%) 0.3% (0.1%-1.0%) 
Adjusted    
  All enrollees 26.8% (25.6%-28.1%) 0.1% (0.0%-0.6%) 
  Low-frequency hospital users only 6.1% (3.8%-9.5%) 0.2% (0.1%-1.0%) 
Source: Authors’ calculations using data on 74,706 hospitalizations between Jan 1st and Dec 1st, 2016 of   
42,794 MassHealth managed care eligible adult members. 
Abbreviations: ACO, accountable care organization; ICC, intraclass correlation coefficient. 
a Pseudo ACOs are created by applying MassHealth’s assignment algorithm to historic member claims and 
encounters. Actual ACO attribution only took effect in 2018. 
Estimates are based on hierarchical generalized linear models with a logit link and a binomial distribution. 
Unadjusted models include random effects only. Adjusted models added fixed effects for age, sex, morbidity, 
















5.1 Summary of Findings 
In this dissertation, we 1) developed  and validated a new CVD risk score, similar 
to the Framingham Risk Score relying only on data available in the MCBS that could be 
applied to specific subgroups, such as elderly Medicare beneficiaries (aim 1); 2) 
illustrated the value of risk adjusting quality measures using morbidity and social 
determinants of health (SDH) factors based on 30-day readmission rates (aim 2); and 3) 
described the characteristics of MassHealth members who are high-frequency hospital 
users and assessed the impact of their inclusion or exclusion on the 30-day readmission 
measure (aim 3).  
Aim 1: 
We showed that existing data on morbidity and functional limitation may partially 
substitute for unavailable direct measures such as clinical and laboratory information in 
MCBS to evaluate CVD risks. Our MCBS-FRS predicted 3-year CVD events better than 
a modification of the FRS that had previously been used in MCBS. The actual CVD 
event percentages for those with the highest 5 and 10 percent of MCBS-FRS predicted 
risk were 9.1% and 10.1%; analogous numbers based on the (previously used) modified 
FRS were lower: 7.5% and 8.1%, respectively. Our CVD risk equation is important 
because it allows for a broader range of analyses for addressing public health and policy 
questions than would not be possible using either survey or Medicare data alone. 10,16 Not 
only does the MCBS include a nationally representative sample of the US elderly, a high 
proportion of whom live with chronic conditions, it also contains a wealth of information 







Moreover, our method of refitting the model in new data (rather than simply using the 
coefficients of the risk factors in the FRS) and including other risk factors, such as 
morbidity and functional limitation, could be replicated to develop specific case-mix 
modified Framingham scores that may be more appropriate for specific databases of 
specific populations. 
Aim 2: 
We used MassHealth claims and enrollment data to measure morbidity burden 82 
and social determinant of health factors such as behavioral health issues (i.e. serious 
mental illness and substance use disorder), disability, and housing instability. We also 
used census data to compute a social stress neighborhood stress score at the US Census-
block-group level from seven neighborhood-level indicators of economic stress available 
through the American Community Survey. 11 We then illustrated the value of risk 
adjusting quality measures for morbidity and SDH factors using all cause 30-day re-
admission rate as an example. We were able to dramatically improve the match between 
actual and expected readmission rates for several subgroups of vulnerable MassHealth 
members. These include members with high morbidity levels, with a disability, with 
behavioral health problems, and those with housing issues. We showed that not adjusting 
quality measures’ performance for morbidities and SDH factors may harm some 
vulnerable populations and the ACOs that serve them. 7,8 Our comprehensive medical and 
SDH-based model development can be replicated by others to facilitate and support care 









With the same data used for aim 2, we described the characteristics of MassHealth 
members who are high-frequency hospital users and assessed the impact of their 
inclusion or exclusion on the 30-day readmission measure. We found that 30-day 
readmission rates increase sharply with numbers of hospitalizations per patient. Thus, a 
small group of MassHealth beneficiaries are responsible for disproportionate 
hospitalization use and have an outsized effect on 30-day readmission and its variability. 
These beneficiaries are sicker than other patients, with significant mental illness, drug 
dependence abuse, and housing issues. A better understanding of which patients may be 
at risk for frequent hospital use is important because many of their initial hospitalizations 
could perhaps be prevented through more effective and targeted interventions. Moreover, 
a better understanding of which patients are at highest likelihood of readmission after 
hospitalization may enable clinicians, ACOs, and policy makers to focus efforts on 
patients who will benefit the most from heath interventions after hospitalization. Our 
study suggests that it might be wise to exclude high-frequency users from the re-
admission measure, and possibly from other quality measures. Doing so will benefit both 
medically and socially complex patients and the ACOs that disproportionally serve them. 
5.2 Limitations and Strengths 
Our aim 1 study has several limitations that must be acknowledged.  First, we 
used survey and claims data to develop our MCBS CVD risk model. These data are 
generally thought to be less accurate than the clinical and laboratory data used in the 







only on information available in MCBS. Second, the FRS was developed using a 10-year 
follow-up period that was not available for MCBS; our MCBS-FRS score predicts CVD 
events within a 2-year follow-up period.  However, identifying individuals at higher CVD 
risk over a relatively short-time period is also important for more timely interventions. 
Intensive early follow-up and more frequent surveillance may improve health and offset 
future costs associated with avoidable health care utilization in this high-risk population. 
Moreover, even though only about 4.40% of our study sample had events within 2 years 
of follow-up, there were enough CVD events to build a stable and credible model.  
Furthermore, since MCBS beneficiaries identified by our CVD risk algorithm can be 
easily linked to Medicare claims data, future studies may easily evaluate their long-term 
CVD health outcomes. Third, the predictors in the MCBS-FRS score, except for the HCC 
disease burden score, were all self-reported, and therefore subject to reporting or recall 
bias. Fourth, we identified CVD outcomes based on claims data, which may include 
“rule-out” diagnosis codes for CVD. 69 70 However, for the major CVD events of AMI 
and stroke, we used ICD-9-CM codes that are specific to new events, mitigating the 
potential for overestimating CVD outcomes. Finally, our results may be representative of 
the Medicare FFS population only. However, complete claims information is required to 
accurately perform our analyses as is usually done in studies of MCBS that are based on 
analysis of claims data. Despite these limitations, we were able to generate a relatively 
powerful CVD risk score that can be computed in MCBS, enhancing the survey’s value 
for health policy and health services research. This CVD risk score, requiring data that 







similarly effective in helping us learn how to reduce CVD events and may allow for a 
more nuanced examination of the costs and benefits of well-targeted health care 
interventions that may be particularly valuable in preventing, managing, and reducing the 
burden of morbidity and mortality associated with CVD. 
Our aim 2 and aim 3 studies also have some limitations. First, it seems likely that 
a model that could account for additional important social risk factors, such as social 
support, health literacy, English proficiency, and functional status – would perform 
better.24,25,84 However, we could use only readily available predictors. MassHealth may 
need to work with ACOs, managed care organizations, and other state entities, such as 
social and housing services, to obtain other factors to augment their data. Having 
additional factors available in the future will add great value to these types of analyses 
and others that address important health policy questions. Second, to improve the 
precision of our prediction models, we controlled for clustering of hospitalizations within 
patients and patients within ACOs that we assigned based on an algorithmic attribution 
using historic member claims and encounters. However, our ACO attribution may differ 
from actual member attribution or assignment under current ACO models that went into 
effect in 2018. Third, our study was limited by a geographically constrained population 
that included MassHealth members only. Priorities and support given to advance 
coverage, access, health outcomes, and efficiency goals expressed by the ACA, may 
differ from state to state. Hence, our findings may not generalize to other states, 
programs, and populations. Despite these limitations, this is the first study to risk-adjust a 







variables. In addition, this study used MassHealth, a large statewide healthcare database. 
In 2015, MassHealth was the primary payer for 70.4% of its membership and a secondary 
payer for eligible residents with other primary insurance coverage, which represented 
28.3% of total MassHealth membership. We were able to identify medically and socially 
disadvantaged Massachusetts Medicaid beneficiaries whose needs should be addressed 
immediately to improve health quality overall, reduce health disparities, and decrease 
spending. 
5.3 Implications and Future Directions 
This dissertation uses available existing databases, making research easier and 
less expensive to perform and findings more reliable and generalizable to the data study 
population compared to newly collected data. Most importantly, this dissertation was able 
to examine potential areas of intervention, such as morbidity and social factors to 
improve hospital readmission and other quality measures and identify vulnerable 
populations to facilitate and support caring for them.  
5.3.1 Controversy regarding risk adjusting quality measures: 
Poorer quality ranking of an ACO that disproportionally serves patients with high 
morbidity levels and with SDH factors may be due to the complexity of these patients 
and the challenge of caring for them. Not risk adjusting performance quality measures 
penalizes ACOs that serve high-risk populations. Moreover, ACOs may not get the 
support needed to continue to care for these vulnerable subpopulations, hence they may 
be reluctant to care for them. However, some worry that risk adjustment will “forgive” 







assumes that differences in quality of health care between ACOs may be due to poor 
performance of their providers and staff. However, this may not be true since these 
differences may be due to the difficulty to care for vulnerable patients. Another argument 
against risk adjusting quality measures is that doing so will mask health disparities, 
making it less likely that they are identified and reduce them. However, not risk adjusting 
also does nothing to reveal disparities. If reducing disparities is a goal, it must be 
separately targeted as an outcome of interest. Despite the controversy, this dissertation 
shows that patient characteristics, such as age, sex, morbidities and SDH factors are 
important drivers of readmissions; adjusting for them may help fairly judging 
readmissions for vulnerable patients and the ACOs that disproportionally serve them. 
Risk adjusting quality measures may protect ACOs that disproportionally serve medically 
and socially complex patients from unfair quality penalties that would otherwise make 
them ineligible for shared savings. These extra dollars may, for instance, help them 
design and implement interventions to facilitate and better the care for vulnerable 
populations. The goal is to incentivize ACOs to overcome barriers to better health 
outcomes for high-risk populations and reduce health disparities.   
5.3.2 About hospital readmission measure: 
Although they are considered good quality metrics and are commonly used, 
readmission measures should include two important aspects: 1) readmissions that are 
related to index hospitalization discharges versus those that are unrelated and 2) 
readmissions that are preventable. 22,91,92 One systematic review has found that between 







done to accurately identify which readmissions are preventable so that focus will be on 
reducing avoidable 30-day readmissions. Moreover, some hospitals and ACOs may have 
high readmission rates only because they may have lower mortality rates or may provide 
easy access to care compared to others with lower readmission rates. 8  Furthermore, 
patients may prefer having a few consecutive hospitalizations with a few days or weeks 
in between during the whole year rather than being hospitalized regularly every three 
months or so; this may not translate as a good quality of care from the perspective of a 
hospital or an ACO. Finally, condition-specific readmission measures and those for 
specific settings may help assess quality of care better than all-cause readmission 
measures. As suggested in this dissertation, specific 30-day readmission measures for 
vulnerable patients with disabilities, or behavioral health problems, and those with 
housing issues could be very helpful in improving health quality and reducing health 
disparities. 93 Despite the limitations of the 30-day readmission measure, risk adjusting it 
or any other quality measure for risk factors can still be useful in identifying vulnerable 
subpopulations who are most likely to incur high costs and have issues that need to be 
addressed with distinct programs. 
5.4 Final Conclusions 
 This dissertation illustrates how statistical models can be used with existing 
databases to provide reasonable estimates of risks and health outcomes in a way than can 
inform health policy. Results from this dissertation provide insights for policy makers 







1) the potential benefits of a proxy for the Framingham cardiovascular disease (CVD) 
risk score, that relies only on variables available in the MCBS, to target health interventions to 
policy-relevant subgroups, such as elderly Medicare beneficiaries based on their risk of 
developing CVD 
2) the benefits of setting appropriate risk-adjusted quality of care standards for 
subpopulations while providing ACOs with additional support to enroll, facilitate, and provide 
excellent care for at-risk subgroups 
3) the outsized effect of high-frequency hospital users on re-admission rates that raises 
questions about how to fairly judge readmissions for medically and socially complex patients 
and the ACOs that disproportionally serve them. 
The models in this dissertation are great tools which can be replicated by policy 
makers, payers, ACOs, and others to identify, facilitate, and support care of high risk and 
specific vulnerable patients by improving their health outcomes. Such modeling is an 


















APPENDICES FOR CHAPTER I: A CARDIOVASCULAR DISEASE RISK 
PREDICTION ALGORITHM FOR USE WITH THE MEDICARE CURRENT 
BENEFICIARY SURVEY 
Table A.1: Predictors of 3-year CVD event among MCBS beneficiaries using logistic 
regression 
 
  Odds Ratio (95% CI) 
Established Framingham score predictors   
Age (per year) 1.04 (1.03-1.06)  
Gender (female) 0.78 (0.65-0.92)  
Diabetes status (yes) 1.73 (1.46-2.05)  
Smoking status   
  Never smoker Reference  
  Former smoker 1.31 (1.08-1.58)  
  Current smoker 1.99 (1.52-2.60)  
Hypertension (yes) 1.46 (1.24-1.71)  
BMI 1.02 (1.00-1.03)  
    
Additional predictors   
HCC morbidity burden score~ 1.22 (1.10-1.34)  
NAGI score! 1.10 (1.04-1.16)  
    
C statistic 67.07  
C statistic after 10-fold cross validation  66.37  
Source: authors’ calculations using MCBS data. 
MCBS= Medicare Current Beneficiary Survey. CVD=cardiovascular disease. 
Data used in these analyses were for Fee-for-Service (FFS) community-dwelling elderly 
beneficiaries first observed in the MCBS between 1999 and 2008 who did not have claims for 
pre-existing CVD in baseline year (i.e. coronary heart disease, intermittent claudication, 
congestive heart failure, stroke or transient ischemic attack). The CVD outcome was defined in 
years 2 or 3 of MCBS by claims for acute CVD event. 
This model included the following covariates: age (continuous), gender (female), diabetes status 
(yes), smoking status (never smoker, former smoker, and current smoker), hypertension (yes), 
BMI (continuous), the hierarchical condition category (HCC) morbidity burden score (range=0-
12), and the NAGI score (measure of health status and independence for the elderly, range=0-5). 










Appendix 2.1: Risk reclassification analysis 
We first categorized our 3-year CVD risk as less than 6% (low risk) and 6% or 
more (high risk) based on our assessment of the specificity and sensitivity plots against 
possible probability cut-offs.  We then computed the Net Reclassification Improvement 
(NRI). The NRI for a new model is the difference in proportions of individuals who 
moved up and down risk categories compared to a reduced or a prior model. It is the sum 
of the reclassification improvement among beneficiaries who experienced the CVD event 
and the reclassification improvement among those who didn’t. For individuals who had a 
CVD event, we assigned 1 for upward reclassification (move to a higher CVD risk 
category), -1 for downward and 0 for people who did not change their risk category. The 
opposite was done for beneficiaries who didn’t have a CVD event.  We then summed 
these individual scores and divided by numbers of people in each group.  We also 
assessed the ability of the additional predictors (i.e.  morbidity and limitation variables) 
in the new model compared to the modified FRS model to improve the discrimination 
between CVD cases and non-cases by computing the Integrated Discrimination 
Improvement (IDI). IDI can be seen as a continuous version of the NRI with probability 
differences used instead of categories. The larger the IDI, the better is the ability of the 








Table A.2: Risk reclassification from the prior modified Framingham model to the 
new model for predicting a CVD event among MCBS beneficiaries 
 







Beneficiaries who experienced a CVD 
event a (4.87%) 
   
Low risk (<6%) 40.13% 21.55% 61.68% 
High risk (>=6%) 8.52% 29.80% 38.32% 
Total 48.65% 51.35% 100.00% 
Beneficiaries who did not experience a 
CVD event (95.13%) 
   
Low risk (<6%) 64.67% 11.97% 76.64% 
High risk (>=6%) 8.16% 15.20% 23.36% 
Total 72.83% 27.17% 100.00% 
MCBS= Medicare Current Beneficiary Survey. Table based on 16,867 observations 
(weighted to represent 63,208,832 people). 
&Our new model is MCBS-based and included the following covariates: age (continuous), 
gender (female), diabetes status (yes), smoking status (never smoker, former smoker, and 
current smoker), hypertension (yes), BMI (continuous), the hierarchical condition category 
(HCC) morbidity burden score (range 0-12), and the NAGI score (measure of health status 
and independence for the elderly, range=0-5). 
* The prior model is the modified FRS and was calculated based on the original FRS 
assuming that MCBS respondents with hypertension had an untreated SBP of 140mmHg 
while respondents without hypertension had a treated SBP of 120 mmHg. 
 Of the beneficiaries who had a CVD event, 21.55% moved to higher CVD risk category 
while 8.52% moved to lower CVD risk category, with a 13.03% (i.e. 21.55-08.52%) 
reclassification improvement. 
On the other hand, 8.16% of individuals who didn’t have a CVD event moved to lower CVD 
risk category while 11.97% moved to higher CVD risk category giving a -3.81% (8.16-







9.22% (13.03-3.81%) which means that the addition of other predictors improved the 
classification for a net of 9 % of beneficiaries. 
The Integrated Discrimination Improvement (IDI) was 2.35 which suggests an improvement 








APPENDICES FOR CHAPTER II: IMPROVING PERFORMANCE ON HEALTH 
QUALITY MEASURES BY ACCOUNTING FOR MORBIDITY AND SOCIAL 
DETERMINANTS OF HEALTH: AN ILLUSTRATION IN 30-DAY READMISSIONS 
Table A.3: Odds ratios of increasingly complex models predicting 30-day 
readmission 
 Risk adjustment for 
age, sex, and 
morbidity 
(1) 
(1) + serious mental 

















Age/gender at discharge 
   
    
  18-24 Female  Ref Ref Ref 
  25-34 Female 1.00 (0.84, 1.19) 0.91 (0.77, 1.08) 0.91 (0.76, 1.08) 
  35-44 Female 0.81 (0.70, 0.94) 0.75 (0.65, 0.86) 0.76 (0.65, 0.87) 
  45-54 Female 0.95 (0.82, 1.10) 0.80 (0.69, 0.93) 0.82 (0.71, 0.95) 
  55-59 Female 0.72 (0.62, 0.83) 0.68 (0.58, 0.78) 0.68 (0.59, 0.78) 
  60-64 Female 0.86 (0.75, 1.00) 0.75 (0.65, 0.87) 0.77 (0.67, 0.89) 
  18-24 Male 0.58 (0.51, 0.67) 0.57 (0.49, 0.65) 0.56 (0.49, 0.65) 
  25-34 Male 0.73 (0.63, 0.84) 0.67 (0.58, 0.77) 0.68 (0.59, 0.78) 
  35-44 Male 0.56 (0.48, 0.66) 0.58 (0.49, 0.68) 0.57 (0.49, 0.67) 
  45-54 Male 0.58 (0.50, 0.68) 0.60 (0.51, 0.70) 0.60 (0.51, 0.70) 
  55-59 Male 0.48 (0.41, 0.57) 0.54 (0.46, 0.64) 0.54 (0.45, 0.63) 
  60-64 Male 0.52 (0.44, 0.61) 0.57 (0.48, 0.67) 0.57 (0.48, 0.67) 
Morbidity burden  (log-
transformed) 
2.22 (2.14, 2.30) 2.04 (1.97, 2.12) 1.99 (1.91, 2.06) 
Behavioral health 
   
  Serious mental illness 
 
1.67 (1.57, 1.77) 1.60 (1.50, 1.70) 
  Substance use disorder 
 
1.49 (1.41, 1.58) 1.46 (1.38, 1.55) 
Disability status b 
  







 Risk adjustment for 
age, sex, and 
morbidity 
(1) 
(1) + serious mental 


















   
  Housing problem c 
  
1.27 (1.20, 1.34) 
  Neighborhood stress score d 
  
0.99 (0.98, 1.00) 
Model performance 
   
  AIC 69,925 69,335 69,089 
  C statistic*100 66.6 68.26 68.77 
Source: Authors’ calculations using data on 74,706 hospitalizations between Jan 1st and Dec 1st, 
2016 of 42,794 MassHealth managed care eligible adult members. 
Abbreviations: AIC, Akaike’s information criterion; ACO, accountable care organization. 
 a Estimates are based on hierarchical generalized linear models with a logit link and a binomial 
distribution. 
b based on entitlement and qualification for specialized services for mental health or 
developmental disabilities in 2016 
c defined as 3+ distinct addresses or homelessness (Z59.0) on claims or encounter records during 
2016. 








Appendix 3.1: Variable definitions 
 
Serious mental illness and substance use disorders were based on the diagnosis-based 
Hierarchical Condition Category (DxCG-HCC): 
Serious mental illness: 
Acute Paranoid Reaction and Confusion 
Schizophrenia 
Other Nonorganic Psychosis 
Delusional Disorder and Paranoid States 
Bipolar Disorder 
Major Depression 
Substance use disorders: 
Drug Induced Hallucinations, Delusions, and Delirium 
Withdrawal and Other Specified Drug-Induced Mental Disorders 
Drug Dependence 
Drug Abuse without Dependence, Except Alcohol and Tobacco 
Alcohol Psychosis 
Alcohol Dependence 
Alcohol Abuse, Without Dependence 
 
Housing problems were identified as unstable housing and through international 
classification of disease (ICD) codes: 
Unstable housing: 
Defined as 3 or more distinct addresses during 12-month 
Homelessness: 
Presence of at least one ICD10 code Z59.0 for homelessness in claims or encounter 
records during 12-month  
 
Neighborhood Stress Score was derived from principal components analysis that 
identified seven neighborhood-level indicators of economic stress using US Census 
block groups with American Community Survey 
The Neighborhood Stress Score (NSS) is a composite measure of economic stress which 
summarizes seven census variables that were identified in a principal components 
analysis on 2013 Massachusetts Medicaid data. The NSS was derived from addresses that 
were geocoded at the census block group level. It was developed by Dr Arlene Ash and 
colleagues at the University of Massachusetts Medical School as part of a project to 
incorporate social determinants of health (SDH) variables into risk adjustment of global 
payment models for MassHealth. 
 
Census variables in the NSS: 
% of families with incomes < 100% of FPL  
% < 200% of FPL  







% of households receiving public assistance  
% of households with no car 
% of households with children and a single parent  








APPENDICES FOR CHAPTER III: SHOULD HIGH-FREQUENCY HOSPITAL 
USERS BE EXCLUDED FROM 30-DAY READMISSION QUALITY MEASURES? 
Table A.4: Risk adjusted odds ratios for 30-day readmission 
  Odds Ratio 
(95% confidence interval) 
Age/gender at discharge 
 
  
  18-24 Female  Ref 
  25-34 Female 0.91 (0.76, 1.08) 
  35-44 Female 0.76 (0.65, 0.87) 
  45-54 Female 0.82 (0.71, 0.95) 
  55-59 Female 0.68 (0.59, 0.78) 
  60-64 Female 0.77 (0.67, 0.89) 
  18-24 Male 0.56 (0.49, 0.65) 
  25-34 Male 0.68 (0.59, 0.78) 
  35-44 Male 0.57 (0.49, 0.67) 
  45-54 Male 0.60 (0.51, 0.70) 
  55-59 Male 0.54 (0.45, 0.63) 
  60-64 Male 0.57 (0.48, 0.67) 
Morbidity burden (log-transformed) 1.99 (1.91, 2.06) 
Behavioral health 
 
  Serious mental illness 1.60 (1.50, 1.70) 
  Substance use disorder 1.46 (1.38, 1.55) 
Disability status 1.29 (1.22, 1.36) 
Housing 
 
  Housing problem 1.27 (1.20, 1.34) 
  Neighborhood stress score 0.99 (0.98, 1.00) 
Model performance 
 
  C statistic*100 68.77 
Source: Authors’ calculations using data on 74,706 hospitalizations 
between Jan 1st and Dec 1st, 2016 of 42,794 MassHealth managed 







Abbreviations: AIC, Akaike’s information criterion; ACO, 
accountable care organization. 
 a Estimates are based on hierarchical generalized linear models 
with a logit link and a binomial distribution. 
b based on entitlement and qualification for specialized services for 
mental health or developmental disabilities in 2016. 
c defined as 3+ distinct addresses or homelessness (Z59.0) on 
claims or encounter records during 2016. 
d measure summarizing seven neighborhood-level indicators of 
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